KR977001713A - 모르폴린 태키키닌 수용체 길항제의 프로드러그(Prodrugs of morpholine tachykinin receptor antagonists) - Google Patents

모르폴린 태키키닌 수용체 길항제의 프로드러그(Prodrugs of morpholine tachykinin receptor antagonists)

Info

Publication number
KR977001713A
KR977001713A KR1019960704865A KR19960704866A KR977001713A KR 977001713 A KR977001713 A KR 977001713A KR 1019960704865 A KR1019960704865 A KR 1019960704865A KR 19960704866 A KR19960704866 A KR 19960704866A KR 977001713 A KR977001713 A KR 977001713A
Authority
KR
South Korea
Prior art keywords
phenyl
morpholine
methyl
fluoro
ethoxy
Prior art date
Application number
KR1019960704865A
Other languages
English (en)
Inventor
콘라드 피 돈
제프리 제이 할
말콤 맥코스
산더 지 밀스
Original Assignee
폴록 도나 엘
머크 앤드 캄파니, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22767887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR977001713(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 폴록 도나 엘, 머크 앤드 캄파니, 인코포레이티드 filed Critical 폴록 도나 엘
Publication of KR977001713A publication Critical patent/KR977001713A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
    • B60R16/00—Electric or fluid circuits specially adapted for vehicles and not otherwise provided for; Arrangement of elements of electric or fluid circuits specially adapted for vehicles and not otherwise provided for
    • B60R16/02—Electric or fluid circuits specially adapted for vehicles and not otherwise provided for; Arrangement of elements of electric or fluid circuits specially adapted for vehicles and not otherwise provided for electric constitutive elements
    • B60R16/037—Electric or fluid circuits specially adapted for vehicles and not otherwise provided for; Arrangement of elements of electric or fluid circuits specially adapted for vehicles and not otherwise provided for electric constitutive elements for occupant comfort, e.g. for automatic adjustment of appliances according to personal settings, e.g. seats, mirrors, steering wheel
    • B60R16/0373—Voice control
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Mechanical Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

본 발명은 염증 질호나, 동통 또는 편두통, 천식 및 구토의 치료에 유용한 태키키닌 수용체 길항체인 하기 화학식(1)의 치환된 헤테로사이클에 관한 것이다.

Description

모르폴린 태키키닌 수용체 길항제의 프로드러그(Prodrugs of morpholine tachykinin receptor antagonists)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (28)

  1. 하기 화학식(1)의 화합물 또는 이의약제학적으로 허용되는 염.
    상기 식에서, R2및 R3은 (1) 수소, (2) 비치환된거나 (a)히드록시, (b) 옥소, (c)C1-6알콕시, (d) 페닐- C1-3알콕시, (e)페닐, (f) -CN,(g)할로, (h)-NR9R10은 [여기서, R9및 R10은 (i) 수소, (ii) C1-6알킬, (iii) 히드록시-C1-5알킬 및 (iv)페닐로부터 독리적으로 선택됨], (i))-NR9COR10[여기서, R9및 R10은 상기 정의된 바와 같음], (j)-NR9CO2R10[여기서, R9및 R1은 상기 정의된 바와 같음], (k)-CON R9R10[여기서, R9및 R10은 상기 정의된 바와 같음], (l)-COR9[여기서, R9는 상기 정의된 바와 같음]및 (m)-CO2R9[여기서, R9는 상기 정의된 바와 같음]으로부터 선택되는 1개 이상의 치환체로 치환된 C1-6알킬, (3) 비치환된거나 (a)히드록시, (b)옥소, (c)C1-6알콕시, (d)페닐-C1-6알케닐, (e)할로, (f)-CN, (g)-NO2, (h)-CF3, (i)-(CH2)M-NR9R10[여기서, m, R9및 R1은 상기 정의된 바와 같음], (j)-NR9COR10[여기서, R9및 R1은 상기 정의된 바와 같음], (k)-NR9CO2R10[여기서, R9및 R1은 상기 정의된 바와 같음], (l) -CON R9R10[여기서, R9및 R10은 상기 정의된 바와 같음],(m)-CO2NR9R10[여기서, R9및 R10은 상기 정의된 바와 같음], (n)-COR9[여기서, R9는 상기 정의된 바와 같음]및 (o)--CO2R9[여기서, R9는 상기 정의된 바와 같음]으로부터 선택되는 1개 이상의 치환체로 치환된 페닐로 이루어진 그룹으로부터 독립적으로 선택되고; 또한 R2및 R3은 함께 결합하여 (a) 시킬로펜틸, (b)시클로헥실 및 (c) 페닐로 이루어진 그룹으로부터 선택되는 카르보실클릭환 [여기서, 카르보시클릭 환은 비치환되거나 (i) C1-6알킬, (ii)C1-6알콕시, (iii) -NR9R10( R9및 R10은 상기 정의된 바와 같음),(iv) 할로 및 (v)트리플루오로메틸로부터 선택되는 1개 이상의 치환체로 치환됨]을 형성하고; 또한 R2와 R2은 함께 결합하여 (a)피롤리디닐, (b)피페리디닐, (c) 피롤릴, (d) 피리디닐, (e) 이미다졸릴, (f) 푸라닐, (g) 옥사졸릴, (h) 티에닐 및 (i)티아졸릴로 이루어지는 그룹으로부터 선택되는 헤테로시클릭 환(여기서, 헤테로시클릭 환은 비치환되거나 (i) C1-6알킬, (ii)옥소, (iii)C1-6알콕시, (iv)-NR9R10( 여기서,R9및 R10은 상기 정의된 바와 같음),(v) 할로 및 (vi)트리플루오로메틸로부터 선택되는 1개 이상의 치환체로 치환됨]을 형성하고; R6, R7및 R8은 (1)수소, (2)비치환되거나 또는 (a)히드록시, (b)옥소, (c) C1-6알콕시, (d)페닐-C1-3알콕시, (e)페닐, (f)-CN, (g)할로, (h)-CONR9R10[ 여기서,R9및 R10은 상기 정의된 바와 같음], (i)-COR90[ 여기서,R9는 상기 정의된 바와 같음]및 (j)-CO2R9[여기서, R9는 상기 정의된 바와 같음]으로부터 선택되는 1개 이상의 치환체로 치환된 C2-6알케닐, (4)C2-6알키닐, (5)비치환되거나 (a)히드록시, (b)C1-6알콕시, (c)C1-6알킬, (d)C2-5알케닐, (e)할로, (f)-CN, (g)-NO2, (h)-CF3,(i)-(CH2)m-NR9R10[여기서, m,R9및 R10은 상기 정의된 바와 같음], (k)-NR9CO2R10[여기서, R9및 R10은 상기 정의된 바와 같음], (l)-CONR9R10[여기서, R9및 R10은 상기 정의된 바와 같음], (m)-CO2NR9R10[여기서, R9및 R10은 상기 정의된 바와 같음], (n)-COR9[여기서, R9는 상기 정의된 바와 같음], 및 (o)-CO2R9[여기서, R9는 상의 정의된 바와 같음]으로부터 선택되는 1개이상의 치환체로 치환된 페닐, (6)할로, (7)-CN, (8)-CF3, (9)-NO2, (10)-SR14(여기서, R14는 수소 또는 C1-5알킬임), (11)-SOR14(여기서, R14는 상기 정의된 바와 같음), (12)-SO2R14(여기서, R14는 상기 정의된 바와 같음), (13)NR9COR10(여기서, R14및 R16은 상기 정의된 바와 같음), (16)NR9CO2R10(여기서, R9및 R10은 상기 정의된 바와 같음). (14)CONR9COR10(여기서, R9및 R10은 상기 정의된 바와 같음), (15)NR9R10(여기서, R9및 R10은 상기정의된 바와 같음), (16)NR9CO2R10(여기서, R9및 R10은 상기 정의된 바와 같음)(17) 히드록시, (18)C1-6알콕시, (19)COR9(여기서, R9는 상기 정의된 바와 같음) (20)CO2R9(여기서, R9는 상기 정의된 바와 같음), (21) 2-피리딜, (22) 3-피리딜, (23) 4-피리딜, (24) 5-테트라졸릴, 25)2-옥사졸릴 및 (26)2-티아졸릴로 이루어진 그룹으로부터 독립적으로 선택되고; R11,R12및 R13은 R6, R7및 R8의 정의들 또는 -OX로부터 독립적으로 선택되고; A는 (1)비치환된거나 (a)히드록시, (b)옥소, (c)C1-6알콕시, (d)페닐-C1-3알콕시, (e)페닐, (f)-CN, (g)할로([여기서, 할로는 플루오로, 클로로, 브로모 또는 요오드임], (h)-NR9R10[여기서, R9및 R10은 상기 정의된 바와 같음], (j)-NR9COR10[여기서, R9및 R10은 상기 정의된 바와 같음], (j)-NR9CO2R10[여기서, R9및 R10은 상기 정의된 바와 같음] 및 (m)-CO2R9[여기서, R9는 상기 정의된 바와 같음]으로부터 선택되는 1개 이상의 치환체로 치환된 C1-6알킬, (2) 비치환되거나 또는 (a)히드록시, (b)옥소, (c)C1-6알콕시, (d)페닐-C1-3알콕시, (e)페닐, (f)-CN, (g)할로, (h)-CONR9R10[여기서, R9및 R10은 상기 정의된 바와 같음], (i)-COR9[ 여기서, R9는 상기 정의된 바와 같음] 및 (j)-CO2R9[여기서, R9는 상기 정의된 바와 같음]으로부터 선택되는 1개 이상의 치환체로 치환된 C2-6알케닐 및 (3)C2-6알킬닐로 이루어진 그룹으로부터 선택되고, B는 헤테로사이클[여기서, 헤테로사이클은
    으로 이루어진 그룹으로부터 선택되고, -X에 더하여 (i)수소, (ii)비치환되거나 또는 할로, -CF3, -OCH3또는 페닐로 치환된 C1-6알킬 (iii)C1-6알콕시, (iv)옥소,(v)히드록시, (vi)티옥소,(vii)-SR9[여기서, R9는 상기 정의된 바와 같음], (viii)할로, (ix)시아노, (x)페닐, (xi)트리플루오로메틸, (xii)-(CH2)m-NR9R10[여기서, m은 0,1 또는 2이고, R9및 R10은 상기 정의된 바와 같음, (xiii)-NR9COR10[여기서, R9및 R10은 상기 정의된 바와 같음], (xiv)-CONR9R10[여기서, R9및 R10은 상기 정의된 바와 같음], (xv)-CO2R9[여기서, R9는 사기 정의된 바와 같음]및 (xvi)-(CH2)m-OR9[여기서, m및 R9는 상기 정의된 바와 같음]으로부터 선택되는 1개 이상의 정의된 바와 같음]및 (xvi)-(CH2)m-OR9(여기서, m및 R9는 상기 정의된 바와 같음]으로부터 선택되는 1개이상의 치환체로 치환됨]이고; p는 0또는 1이고; X는 (a)-PO(OH)O-·M*(여기서, M*는 약제학적으로 허용되는 1가 역이온임), (b)-PO(O-)2·2M*,(c)-PO(O-)2·D2*(여기서, D2*는 약제학적으로 허용되는 2가 역이온임), (D)-CH(R4)-PO(OH)O-·M*(여기서, R4는 수소 또는 C1-3알킬임), (e)-CH(R4)-PO(O-)2·2M+, (f)-CH(R4)-PO(O-)2·D2 +,(g)-SO3 -·M+; (h)-CH(R4)-SO3-·M+,(i)-CO-CH2CH2-CO2 -·M+; (j)-CH(CH3)-O-CO-R5[여기서, R5는
    으로 이루어진 그룹으로부터 선택됨]및 (k)수소[단, p가 0이고, R11,R12또는 R13중 어느 것도 -OX가 아닌 경우에는 X는 수소가 아님)으로부터 선택되고; Y는 (1)단일 결합, (2)-O-, (3)-S-, (4)-CO-, (5)-CH2-(6)-CHR15, 및 (7)-CR15R16-[여기서, R15및 R16은 (a)비치환되거나 또는(i)히드록시, (ii)옥소, (iii)C1-6알콕시, (iv)페닐-C1-4알콕시, (v) 페닐, (vi)-CN, (vii)할로, (viii)-NR9R10[여기서, R9및 R10은 상기 정의된 바와 같음], (ix)-NR9COR10[여기서, R9및 R10은 상기 정의된 바와 같음], (x)-NR9CO3R10[여기서, R9및 R10은 상기 정의된 바와 같음]. (xi)-CONR9R10[여기서, R9및 R10은 상기 정의된 바와 같음], (xii)-COR9[여기서, R9는 상기 정의된 바와 같음], 및 (xiii)-CO2R9[여기서, R9는 상기 정의된 바와 같음]으로부터 선택된느 1개 이상의 치환체로 치환된 C1-6알킬 및 (b)비치환되거나 또는 (i)히드록시, (ii)C1-6알콕시, (iii)C1-6알킬, (iv)C2-5알케닐, (v)할로, (vi)-CN, (vii)-NO2, (viii)-CF3, (ix)-(CH2)m-NR9R10[여기서, m, R9및 R10은 상기 정의된 바와 같음], (x)-NR9COR10[여기서, R9및 R10은 상기 정의된 바와 같음], (xi)-NR9CO2R10[여기서, R9및 R10은 상기 정의된 바와 같음], (xii)-CONR9R10[여기서 R9및 R10은 상기 정의된 바와 같음], (xiii)-CO2NR9R10[여기서, R9및 R10은 상기 정의된 바와 같음], (xiv)-COR9[여기서, R9는 상기 정의된 바와 같음] 및 (xv)-CO2R9[여기서, R9는 상기 정의된 바와 같음]으로부터 선택되는 1개 이상의 치환체로 치환된 페닐로 이루어진 그룹으로부터 독립적으로 선택됨] Z는 히드록시가 아니거나, 또는 Y가 -CHR15-인 경우에는 Z및 R15는 임의로 함께 겨합하여 이중 겨합을 형성함]으로부터 선택된다.
  2. 제1항에 있어서, R2및 R3이 (1)수소 (2) C1-6알킬, (3)C3-6알케닐 및 (4) 페닐로 이루어진 그룹으로부터 독립적으로 선택되고; R6, R7및 R8이 (1)수소, (2)C1-6알킬, (3)플루오로, (4) 클로로, (5) 브로모, (6) 요오도, 및 (7)-CH3로 이루어진 그룹으로부터 독립적으로 선택되고; R11, R12, 및R13이 (1)플루오로, (2)클로로, (3) 브로모, 및(4) 요오도로 이루어진 그룹으로부터 독립적으로 선택되고; A가 치환된 C1-6알킬이며; B가
    으로 이루어진 그룹으로부터 선택되고; p가 0이고; X가 (a) -PO(OH)O-·M*(여기서, M*는 약제학적으로 허용되는 1가 역이온임),(d)-PO(O-·M*(여기서, R4는 수소 또는 메틸임), (e)-CH(R4)-PO(O-)2·2M-(여기서, R4는 수소 또는 메탈임), (f)-CH(R4)-PO(O-)2·D2·(여기서, R4는 수소 또는 메탈임), (i)-CO-CH2CH2-CO2-·M*및 (j)-CH(CH3)-O-CO-R5(여기서, R5는
    으로 이루어진 그룹으로부터 선택됨(로 부터 선택되고; Y가 -O-이고; Z가 수소 또는 C1-4알칼인 화합물.
  3. 제1항에 있어서, Z가 C1-4알칼인 화합물.
  4. 제1항에 있어서, Z가 -CH3인 화합물.
  5. 제1항에 있어서, A가 -CH3- 또는 -CH(CH3)-인 화합물.
  6. 제1항에 있어서, -B가
    으로 이루어진 그룹으로부터 선택되는 화합물.
  7. 제1항에 있어서, -A-B가
    으로 이루어진 그룹으로부터 선택되는 화합물.
  8. 제1항에 있어서, -A-B가
    으로 이루어진 그룹으로부터 선택되는 화합물.
  9. 제1항에 있어서, X가 (a)-PO(O-)2·2M-(여기서, M-는 약제학적으로 허용되는 1가 역이온임), (b)-PO(O-)2·D2·(여기서, D2 *는 약제학적으로 허용되는 2가 역이온임), (c)-CH(CH2)-O-C-CH2CH2-NH3 *·M*, 및(d)-CH(CH3)-O-CO-CH2C2-NH2 *-(CH2CH2-H)·M*로 이루어진 그룹으로부터 선택되는 화합물.
  10. 제1항에 있어서, 하기 화학식(2)의 화합물 또는 이의 약제학적으로 허용되는 염.
    상기 식에서, R2,R3,R6,R7,R8,R11,R12,R13,A,B 및 Z는 제1항에서 정의된 바와 같다.
  11. 제1항에 있어서, 하기 화학식(3)의 화합물 또는 이의 약제학적으로 허용되는 염.
    상기 식에서, R2,R3,R6,R7,R8,R11,R12,R13,A,B및 Z는 제1항에서 정의한 바와 같다.
  12. (1)2-(S)-(3,5-비스(트리플루오로메틸)벤질옥시)-3-(S)-페닐-4(-3-옥소- 1H,4H-1,2,4-트리아졸로)메틸)모프폴린 N-옥시드; (2) 2-(S)-(3,5-비스(트리플루오로메틸)벤질옥시)-3-(S)-페닐-4-(3-(4-(에톡시카르보닐옥시-1-에틸)5-옥소-1H-1,2,4-트라아졸로)메틸)모르폴린; (3) 2-(R)-(1-(R)-(3,5-비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(4-모노포스포릴-5-옥소-1H-1,2,4-트리아졸로)메틸)모르폴린; (4) 2-(R)-(1-(R)-(3,5-비스(트리플루오로메틸)페닐)에톡시)--(S)-(4-플루오로)-페닐-4-(3-(1-모노포스포릴-5-옥소-1H-1,2,4-트리아졸로)메틸)모르폴린; (5) 2-(R)-(1-(R)-(3,5-비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(4-플루오로)-페닐-4-(3-2(-모노포스포릴-5-옥소-1H-1,2,4-트리아졸로)메틸)모르포린;(6) 2-(R)-(1-(R)-(3,5-비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(4-플루오르)-페닐-4-(3--5-옥시포스포릴-1H-1,2,4-트리아졸로)메틸)모르포린 및 (7) 2-(S)-(1-(R)-(3,5-비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(4-플루오로)-페닐-4-(3-(1-포스포릴-5-옥소-4H-1,2,4-트리아졸로)메틸)모르포린으로 이루어진 그룹으로부터 선택되는 화합물 또는 이의 약제학적으로 허용되는 염.
  13. 제12항에 있어서, 약제학적으로 허용되는 염이 비스(N-메틸-D-글루카민)염인 화합물.
  14. (여기서, K*는 약제학적으로 허용되는 역이온이다)으로 이루어진 그룹으로부터 선택되는 화합물.
  15. 하기 스펙트럼 데이타를 특징으로 하는 화합물.
    1H NMR (CD3OD,500MHz,ppm) : δ1.43(d, J=6.5Hz,3H(, 2.45(app t, J=8.5Hz,1H(, 2.80(d, J=14.0Hz,1H), 2.92(d, J=11.5Hz,1H), 3.47∼3.66(m,44h), 4.25(app t, J=11.5Hz,1H), 4.36(d,J=1.5Hz,1H), 4.95(q, J=6.6Hz,1H), 7.05(t,J=8.5Hz,2H), 7.52(br s, 2H), 7.71(s,1H);13C NMR(CD3OD, 125MHz,ppm);δ24.7, 52.3, 53.4, 60.5, 70.6, 73.7, 97.2, 116.1(d, J=21.9Hz), 122.3, 124.6(q,J=271.OHz),127.7, 132.3, 132.6, 132.8 134.3, 145.2(d,J=11.0Hz), 147.5, 159.0(d,J=10.1Hz), 164.0(d,J=244,4Hz).
  16. 1) (+/-)-2-(3.5-비스(트리플루오로메틸)벤질옥시)-3-페닐-모르폴린; 2) (2R,S)-(3,5-비스(트리플루오로메틸)벤질옥시)-(3R)-페닐-(6R)-메틸-모르폴린; 3) (2R,S)-3,5-비스(트리플루오로메틸)벤질옥시)-(3S)-페닐-(6R)-메틸-모르폴린; 4) (+/-)-2-(3,5-비스(트리플루오로메틸)벤질옥시)-3-페닐-4-메틸카르복사미도-모르폴린; 5) (+/-)-2-(3,5-비스(트리플루오로메틸)벤직옥시)-3-페닐-4-메틸카르복사미도-모르폴린; 5) (+.-)-2-(3,5-비스(트리플루오로메틸)벤질옥시)-3-페닐-4-메톡시-칼보닐메틸-모르폴린;; 6) 2-(2-3,5-비스(트리플루오로메틸)페닐)-에틸)-3-페닐-5-옥소-모르폴린; 7) 3-페닐-2-(3-(3,5-비스(트리플루오로메틸)페닐)-에틸)-모르폴린; 8)2-(R)-(3,5-비스(트리플루오로메틸)벤질옥시)-3-(R)-페닐-6-(S)-메틸-모르폴린; 9) 2-(R)-(3,5-비스(트리플루오로메틸)벤질옥시)-3-(R)-페닐-6-(S)-메틸-모르폴린; 10) 2-(S)-3,5-비스(트리플루오로메틸)벤질옥시)-3-(R)-페닐-6-(S)-메틸-모르폴린; 11) 2-(S)-3,5-비스(트리플루오로메틸)벤질옥시)-3-(R)-페닐-6-(S)-메틸-모르폴린; 12) 2-(R)-3,5-비스(트리플루오로메틸)벤질옥시)-3-(R)-페닐-6-(R)-메틸-모르폴린; 13) 2-(R)-3,5-비스(트리플루오로메틸)벤질옥시)-3-(R)-페닐-6-(R)-메틸-모르폴린; 14) 2-(S)-3,5-비스(트리플루오로메틸)벤질옥시)-3-(R)-페닐-6-(R)-메틸-모르폴린; 15) 2-(R)-3,5-비스(트리플루오로메틸)벤질옥시)-3-(S)-페닐-6-(R)-메틸-모르폴린; 16) 2-(S)-3,5-비스(트리플루오로메틸)벤질옥시)-3-(S)-페닐-모르폴린; 17)4-(3-(1,2,4-트리아졸로)메틸)-2-(S)-(3,5-비스(트리플루오로메틸)벤질옥시)-3-(S)-페닐-모르폴린; 18)4-(3-(5-옥소-1H,4H,-1,2,4-트리아졸로)메틸)-2-(S)-(3,5-비스(트리플루오로메틸)벤질옥시)-3-(S)-페닐-모르폴린; 19) 2-(R)-(3,5-비스(트리플루오로메틸)벤질옥시)-3-(R)-페닐-6-(R)-메틸-모르폴린; 20) 2-(S)-(3,5-비스(트리플루오로메틸)벤질옥시)-3-(R)-페닐-6-(R)-메틸-모르폴린; 21) 2-(R)-(3,5-비스(트리플루오로메틸)벤
    질옥시)-3-(S)-페닐-6-(R)-메틸-모르폴린; 22) 2-(S)-(3,5-비스(트리플루오로메틸)벤질옥시)-3-(S)-페닐-6-(R)-메틸-모르폴린; 23) 2-(R)-(3,5-비스(트리플루오로메틸)벤질옥시)-3-(S)-페닐-5-(S)-메틸-모르폴린; 24) 2-(S)-(3,5-비스(트리플루오로메틸)벤질옥시)-3-(S)-페닐-5-(S)-메틸-모르폴린; 25) 2-(R)-(3,5-비스(트리플루오로메틸)벤질옥시)-3-(R)-페닐-5-(S)-메틸-모르폴린; 26) 2-(R)-(3,5-비스(트리플루오로메틸)벤질옥시)-3-(S)-페닐-5-(R)-페닐-모르폴린; 27) 2-(S)-(3,5-비스(트리플루오로메틸)벤질옥시)-3-(S)-페닐-5-(R)-페닐-모르폴린; 28) 2-(S)-(3,5-비스(트리플루오로메틸)벤질옥시)-3-(R)-페닐-5-(R)-페닐-모르폴린; 29) 2-(R)-(3,5-비스(트리플루오로메틸)벤질옥시)-3-(R)-페닐-5-(R)-페닐-모르폴린; 30) 2-(S)-(3,5-비스(트리플루오로메틸)벤질옥시)-6-(R)-메틸-3-(S)-페닐-4-(3-(1,2,4-트리아조로)메틸)-모르폴린; 31)2-(S)-(3,5-비스(트리플루오로메틸)벤질옥시)-6-(R)-메틸-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-3-(S)-페닐-모르폴린; 32) 2-(S)-(3,5-비스(트리플루오로메틸)벤질옥시)-3-(R)-페닐-모르폴린; 33) 4-(3-(5-옥소-1H, 4H-1,2,4-트리아졸로)메틸)-2-(S)-(3,5-비스(트리플루오로메틸)벤질옥시)-3-(R)-페닐-모르폴린; 34) 4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-2-(S)-(3,5-비스(트리플루오로메틸)벤질옥시)-3-(R)-페닐-모르폴린; 35) 4-(2-(이미다졸로)메틸)-2-(S)-(3,5-비스(트리플루오로-메틸)-벤질옥시)-3-(R)-페닐-모르폴린; 36) 4-(4-(이미다졸로)메틸)-2-(S)-(3,5-비스(트리플루오로메틸)-벤질옥시)-3-(R)-페닐-모르폴린; 37) 4-(아미노카르보닐메틸)-2-(S)-(3,5-비스(트리플루오로메틸)-벤질옥시)-3-(R)-페닐-모르폴린; 38) 4-(2-(이미다졸로)메틸)-2-(S)-(3,5-비스(트리플루오로메틸)-벤질옥시)-3-(S)-페닐-모르폴린; 39) 4-(4-(이미다졸로)메틸)-2-(S)-(3,5-비스(트리플루오로메틸)-벤질옥시)-3-(S)-페닐-모르폴린; 40) 4-(2-(이미다졸로)메틸)-2-(S)-(3,5-비스(트리플루오로메틸)-벤질옥시)-3-(S)-페닐-6-(R)-메틸-모르폴린; 41)4-(4-(이미다졸로)메틸)-2-(S)-(3,5-비스(트리플루오로메틸)-벤질옥시)-3-(S)-페닐-6(R)-메틸-모르폴린; 42) 2-(S)-(3,5-비스(트리플루오로메틸)벤질옥시)-4-((6-히드록시)-헥실)-3-(R)페닐-모르폴린; 43) 2-(S)-(3,5-비스(트리플루오로메틸)벤질옥시)-4-(5-(메틸아미노카르보닐)펜틸)-3-(R)-페닐-모르폴린; 44) 4-(3-)1,2,4-트리아졸로)메틸)-2-(3,5-디메틸벤질옥시)-3-페닐모르폴린; 45) 4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-2-(3,5-디메틸)벤질옥시)-3-페닐0모르폴린; 46) 4-(3-(1,2,4-트리아졸)메틸-2-(3,5-디(3급-부틸)-벤질옥시)-3-페닐-모르폴린; 47) 4-(3-(5-옥소-1H, 4H-1,2,4-트리아졸로)메틸)-2-(3,5-디(3급-부틸)-메틸벤질옥시)-3-페닐-모르폴린; 48) 4-(3-(1,2,4-트리아졸)메틸-2-(3-(3급-부틸)-5-벤질옥시)-3-페닐-모르폴린; 49) 4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-2-(3-(3급-부틸)-5-메틸벤질옥시)-3-페닐-모르폴린; 50) 4-(3-(1,2,4-트리아졸로)메틸-2-(3-트리플루오로-메틸)-5-메틸-벤질옥시)-3-페닐-모르폴린; 51) 4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-2-(3-트리플루오로-메틸)-5-벤질옥시)-3-페닐-모르폴린; 52) 4-(3-(1,2,4-트리아졸로)메틸)-2-(3-(3급-부틸)-5-(트리플루오로-메틸)벤질옥시)-3-페닐-모르폴린; 53) 4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-2-(3-3급-부틸)-5-(트리플루오로메틸)벤질옥시)-3-페닐-모르폴린; 54) 4-(2-(이미다졸로)메틸)-2-(3,5-디메틸-벤질옥시)-3-페닐-모르폴린; 55) 4-(4-(이미다졸로)메틸)-2-(3,5-디메틸-벤질옥시)-3-페닐-모르폴린; 56) 4-(2-(이미다졸로)메틸)-2-(3,5-디(3급-부틸)-벤질옥시)-3-페닐-모르폴린; 57) 4-(4-(이미다졸로)메틸)-2-(3,5-디(3급-부틸)-벤질옥시)-3-페닐-모르폴린; 58) 4-(2-(이미다졸로)메틸)-2-(3-(3급-부틸)-5-메틸벤질옥시)-3-페닐-모르폴린; 59) 4-(4-(이미다졸로)메틸)-2-(3-(3급-부틸)-5-메틸벤질옥시)-3-페닐-모르폴린; 60) 4-(2-(이미다졸로)메틸)-2-(3-트리플루오로-메틸)-5-메틸-벤질옥시)-3-페닐-모르폴린; 61) 4-(4-(이미다졸로)메틸)-2-(3-트리플루오로-메틸)-5-메틸-벤질옥시)-3-페닐-모르폴린; 62) 4-(2-(이미다졸로)메틸)-2-(3-(3급-부틸)-5-(트리플루오로메틸)-벤질옥시)-3-페닐-모르폴린; 63) 2-(S)-(3,5-디클로로벤질옥시)-3-(S)-페닐-모르폴린; 64) 2-(S)-(3,5-디클로로벤질옥시)-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-3-(S)-페닐모르폴린; 65) 2-(S)-(3,5-비스(트리플루오로메틸)벤질옥시)-4-(메톡시카르보닐-메틸-3-(S)-페닐-포르폴린; 66) 2-(S)-(3,5-비스)트리플루오로메틸)벤질옥시)-4-(카르복시메틸)-3-(S)-페닐-모르폴린; 67) 2-(S)-(3,5-비스(트리플루오로메틸)벤질옥시)-4-((2-아미노에틸)-아미노카르보닐메틸)-3-(S)-페닐-모르폴린; 68) 2-(S)-(3,5-비스(트리플루오로메틸)벤질옥시)-4-((3-아미노프로필)-아미노 카르보닐메틸)-3-(S)-페닐모르폴린; 69) 4-벤질-5-(S), 6-(R)-디메틸-3-(S)-페닐모르폴리논 및 4-벤질-5-(R), 6-(S)-디메틸-3-(S)-페닐-모르폴리논; 70) 2-(R)-(3,5-비스(트리플루오로메틸)벤질옥시)-[5-(S),6-(R) 또는 5-(R), 6-(S)-디메틸]-3-(S)-페닐-모르폴리논; 71)2-(S)-(3,5-비스)트리플루오로메틸)벤질옥시)-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-[5-(S), 6-(R) 또는 5-(R), 6-(S)-디메틸]-3-(S)-페닐-모르폴리논; 72) 2-(R)-(3,5-비스(트리플루올메틸)벤질옥시)-4-(3-(5-1,2,4-트리아졸로메틸)-[5-(S), 6-(R) 또는 5-(R), 6-(R)-디메틸]-3-(S)-페닐-모르폴리논; 73) 2-(R)-(3,5-비스(트리플루올메틸)벤질옥시)-4-(3-(5-1,2,4-트리아졸로메틸)-[5-(S), 6-(R) 또는 5-(R), 6-(R)-디메틸]-3-(S)-페닐-모르폴리논; 74) 2-(S)-(3,5-비스(트리플루올메틸)벤질옥시)-4-(3-(5-1,2,4-트리아졸로메틸)-[5-(R), 6-(S) 또는 5-(S), 6-(R)-디메틸]-3-(S)-페닐-모르폴리논; 75) 2-(S)-(3,5-비스(트리플루올메틸)벤질옥시)-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-[5-(R), 6-(S) 또는 5-(S), 6-(R)-디메틸]-3-(S)-페닐-모르폴리논; 76) 2-(S)-3,5-비스(트리플루올메틸)벤질옥시)-4-(2-(1-(4-벤질)-피페리디노)에틸)-3-(S)-페닐-모르폴린; 77) 3-(S)-(4-플루오로페닐)-4-벤질-2-모르폴리논; 78) 2-(S)-(3,5-비스(트리플루오로메틸)벤질옥시)-3-(S)-(4-플루오로-페닐)-4-벤질-모르폴린; 79) 2-(S)-(3,5-비스(트리플루오로메틸)벤질옥시)-3-(S)-(4-플루오로-페닐)모르폴린; 80) 2-(S)-(3,5-비스(트리플루오로메틸)벤질옥시)-3-(S)-(4-플루오로-페닐)-4-(3-(5-옥소-1H,4H, -1,2,4-트리아졸로(메틸-모르폴린; 81)2-(S)-(3,5-비스(트리플루오로메틸)벤질옥시)-4-((3-피리딜(메틸카르보닐)-3-(R)-페닐-모르폴린; 82) 2-(S)-(3,5-비스(트리플루올메틸)벤질옥시)-4-(메톡시카르보닐-펜틸))-3-(R)-페닐-모르폴린; 84) 2-(S)-(3,5-비스(트리플루오로메틸)벤질옥시)-4-(메틸아미노-카르보닐펜틸)-6-옥소-헥실)-3-(R)-페닐-모르폴린; 85) 2-(R)-(3,5-비스(틀플루오로메틸)벤조일옥시)-3-(S)-페닐-4-벤질-모르폴린; 86) 2-(R)-(1-3,5-비스(트리플루오로메틸)페닐)엑테닐옥시)-3-(S)-페닐-4-벤질-모르폴린; 87) 2-(R)-(1-(S)-(3,5-비스(트리플루오로메틸)페닐)에톡시)-3-(S)-페닐-모르폴린; 88) 2-(R)-(1-(R)-(3,5-비스(트리플루오로메틸)페닐)에톡시)-3-(S)-페닐-모르폴린; 89) 2-(R)-(1-(S)-(3,5-비스(트리플루오로메틸)페닐)에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸-모르포린; 90) 2-(R)-(1-(R)-(3,5-비스(트리플루오로메틸)페닐)에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸-모르포린; 91) 2-(R)-(3,5-비스(트리플루오로메틸)벤질옥시)-3-(S)-(4-플루오로)-페닐-4-벤질-모르폴린; 92) 2-(R)-(1-(R))-(3,5-비스(트리플루오로메틸)페닐)에텔닐옥시)-3-(S)-(4-플루오로)-페닐-4-벤질-모르폴린; 93) 2-(R)-(1-(S)-(3,5-비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(4-플루오로)페닐-모르폴린; 94) 2-(R)-(1-(R))-(3,5-비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(4-플루오로)페닐-모르폴린; 95) 2-(R)-(1-(S)-(3,5-비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸-모르포린; 96) 2-(R)-(1-(S)-(3,5-비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸-모르포린; 97) 2-(R)-(1-(R)-(1-(3-(메틸)나프틸)에톡시)-3-(S)-페닐-4-(3-(1,2,4-트리아졸로)메틸-모르폴린; 98) 2-(R)-(1-(R)-(1-(3-(메틸)나프틸)에톡시)-3-(S)-페닐-4-(4-(2-옥소-1,-이미다졸로)메틸-모르폴린; 99) 2-(R)-(1-R)-(3-(플루오로)-5-(트리플루오로메틸)페닐)에톡시)-3-(S)-페닐-모르폴린; 100) 2-(R)-(1-(R)-(3-플루오로)-5-(트리플루오로메틸)페닐)에톡시)-3-(S)-페닐-4-(4-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 101) 2-(R)-(1-(R)-(3-(클로로)-5-(트리플루오로메틸)페닐)에톡시)-3-(S)-페닐-모르폴린; 102) 2-(R)-(1-(R)-(3-(클로로)-5-(트리플루오로메틸)페닐)에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 103) 2-(R)-(1-(R)-(3,5-(디메틸)페닐)에톡시)-3-(S)-페닐-모르폴린; 104) 104)2-(R)-(1-(R)-(3,5-(디메틸)페닐)에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 105) 2-(R)-(1-(R)-(3-(플루오로)-5-(메틸)페닐)에톡시)-3-(S)-페닐-모르폴린; 106) 2-(R)-(1-(R)-(3-(플루오로)-5-(메틸)페닐)에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 107) 2-(R)-(1-(R)-(3-(클로로)-5-(메틸)페닐)에톡시)-3-(S)-페닐-모르폴린; 108) 2-(R)-(1-(R)-(3-(클로로)-5-(메틸)페닐)에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 109) 2-(R)-(1-(R)-(3-(브로모)-5-(메틸)페닐)에톡시)-3-(S)-페닐-모르폴린; 110) 2-(R)-(1-(R)-(3-(브로모)-5-(메틸)페닐)에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 111) 2-(R)-(1-(R)-(3-(이소프로폭시)페닐)에톡시)-3-(S)-페닐-모르폴린; 112) 2-(R)-(1-(R)-(3-(이소프로폭시)페닐)에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 113) 2-(R)-(1-(R)-(3-(이소프로폭시)-5-트리플루오로메틸)페닐)에톡시)-3-(S)-페닐-모르폴린; 114) 2-(R)-(1-(R)-(3-(이소프로폭시)-5-트리플루오로메틸)페닐)에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 115) 2-(R)-(1-(R)-(3-(클로로)-5-(이소프로폭시)페닐)에톡시)-3-(S)-페닐-모르폴린; 116) 2-(R)-(1-(R)-(3-(클로로)-5-(이소프로폭시)페닐)에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 117) 2-(R)-(1-(R)-(3-(플루오로)-5-(이소프로폭시)페닐)에톡시)-3-(S)-페닐-모르폴린; 118) 2-(R)-(1-(R)-(3-(플루오로)-5-(이소프로폭시)페닐)에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 119) 2-(R)-(1-(R)-(1-(3-트리플루오로메틸)나프틸))에톡시-3-(S)-페닐-4-(3-(1,2,4-트리아졸ㄹ)메틸)-모르폴린; 120) 2-(R)-(1-(R)-(1-(3-트리플루오로메틸)나프틸))에톡시-3-(S)-페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸-모르폴린; 121) 2-(R)-(1-(R)-(1-(3-(t-부틸)-5-(클로로)페닐)에톡시)-3-(S)-페닐-모르폴린; 122) 2-(R)-(1-(R)-(3-(t-부틸)-5-(클로로)페닐)에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 123) 2-(R)-(1-(R)-(3-(t-부틸)-5-(트리플루오로메틸)페닐)에톡시)-3-(S)-페닐-모르폴린; 124) 2-(R)-(1-(R)-(3-(t-부틸)-5-(트리플루오로메틸)페닐)에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 125) 2-(R)-(1-(R)-(3,5-(디메틸)-4-(플루오로)페닐)에톡시)-3-(S)-페닐-모르폴린; 126) 2-(R)-(1-(R)-(3,5-(디메틸)-4-(플루오로)페닐)에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 127)2-(R)-(1-(R)-(3,5-(디메틸)-4-(클로로)페닐)에톡시)-3-(S)-페닐-모르폴린; 128) 2-(R)-(1-(R)-(3,5-(디메틸)-4-(클로로)페닐)에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 129) 2-(R)-(1-(R)-(3,5-비스(트리플루오로메틸)-4-(플루오로)페닐)에톡시)-3-(S)-페닐-모르폴린; 130) 2-(R)-(1-(R)-(3,5-비스(트리플루오로메틸)-4-(플루오로)페닐)에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 131) 2-(R)-(1-(R)-(3,5-비스(트리플루오로메틸)-4-(클로로)페닐)에톡시)-3-(S)-페닐-모르폴린; 132) 2-(R)-(1-(R)-(3,5-비스(트리플루오로메틸)-4-(클로로)페닐)에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 133) 2-(R)-(1-(R)-(3,5-(디클로로)페닐)에톡시)-3-(S)-페닐-모르폴린; 134) 2-(R)-(1-(R)-(3,5-(디클로로)페닐)에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 135) 2-(R)-(1-(R)-(3,5-(디플루오로)페닐)에톡시)-3-(S)-페닐-모르폴린; 136) 2-(R)-(1-(R)-(3,5-(디플루오로)페닐)에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 137) 2-(R)-(1-(R)-(1-(나프틸)에톡시)-3-(S)-페닐-모르폴린; 138) 2-(R)-(1-(R)-(1-(나프틸)에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 139) 2-(R)-(1-(R)-(1-(4-플루오로)나프틸))에톡시)-3-(S)-페닐-모르폴린; 140) 2-(R)-(1-(R)-(1-(4-플루오로)나프틸))에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 141) 2-(R)-(1-(R)-(1-3-(플루오로)나프틸))에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 142) 2-(R)-(1-(R)-(1-3-(플루오로)나프틸))에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 143) 2-(R)-(1-(R)-(1-(3-(클로로)나프틸))에톡시)-3-(S)-페닐-모르폴린; 144) 2-(R)-(1-(R)-(1-(3-(클로로)나프틸))에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 145) 2-(R)-(1-(R)-(1-(3-(메틸)나프틸))에톡시)-3-(S)-페닐-모르폴린; 146) 2-(R)-(1-(R)-(1-(3-(메틸)나프틸))에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 147) 2-(R)-(1-(R)-(1-(3-(트리플루오로메틸)나프틸))에톡시)-3-(S)-페닐-모르폴린; 148) 2-(R)-(1-(R)-(1-(3-(트리플루오로메틸)나프틸))에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 149) 2-(S)-(3,5-비스)트리플루오로메틸)벤질옥시)-3-(S)-(4-히드록시)-페닐-모르폴린; 150)2-(S)-(3,5-비스)트리플루오로메틸)벤질옥시)-3-(S)-(4-히드록시)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 151) 2-(S)-(2-플루오로-5-트리플루오로메틸)벤질옥시-3-(S)-페닐-모르폴린; 152) 2-(S)-(2-플루오로-5-트리플루오로메틸)벤질옥시-3-(S)-(4-플루오로)페닐-모르폴린; 153) 2-(R)-(1-(R)-(2-플루오로-5-트리플루오로메틸)페닐에톡시-3-(S)-페닐-모르폴린; 154) 2-(R)-(1-(R)-(2-플루오로-5-트리플루오로메틸)페닐에톡시-3-(S)-(4-플루오로)페닐-모르폴린; 155)2-(S)-(2-플루오로-5-트리플루오로메틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-모르폴린; 156)2-(S)-(2-플루오로-5-트리플루오로메틸)벤질옥시-3-(S)-(4-플루오로)페닐-4-(3-(1,2,4-트리졸로)메틸-모르폴린; 157) 2-(R)-(1-(R)-(2-플루오로-5-트리플루오로메틸)페닐에톡시)-3-(S)-페닐-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 158) 2-(R)-(1-(R)-(2-플루오로-5-트리플루오로메틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 159) 2-(S)-(2-플루오로-5-트리플루오로메틸)벤질옥시-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 160)2-(S)-(2-플루오로-5-트리플루오로메틸)벤질옥시-3-(S)-(4-플루오로)페닐-4-(3-5-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 161) 2-(R)-(1-(R)-(2-플루오로-5-트리플루오로메틸)페닐에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H, 4H-1,2,4-트리아졸로)메틸-모르폴린; 162) 2-(R)-(1-(R)-(2-플루오로-5-트리플루오로메틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 163) 2-(S)-(2-플루오로-5-트리플루오로메틸)벤질옥시-3-(S)-페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 164) 2-(S)-(2-플루오로-5-트리플루오로메틸)벤질옥시-3-(S)-페닐-4-(4-플루오로)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 165) 2-(R)-(1-(R)-(2-플루오로-5-트리플루오로메틸)페닐에톡시)-3-(S)-페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 166) 2-(R)-(1-(R)-(2-플루오로-5-트리플루오로메틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 167) 2-(S)-(2-플루오로-5-트리플루오로메틸)벤질옥시-3-(S)-페닐-4-(2-이미다졸로)메틸)-모르폴린; 168) 2-(S)-(2-플루오로-5-트리플루오로메틸)벤질옥시-3-(S)-(4-플루오로)페닐-4-(2-이미다졸로)메틸)-모르폴린; 169) 2-(R)-(1-(R)-(2-플루오로-5-트리플루오로메틸)페닐에톡시)-3-(S)-페닐-4-(2-이미다졸로)메틸-모르폴린; 170) 2-(R)-(1-(R)-(2-플루오로-5-트리플루오로메틸)페닐에톡시)-3-(S)-페닐-(4-플루오로)페닐-4-(2-이미다졸로)메티-모르폴린; 171) 2-(S)-2(-플루오로-5-트리플루오로메틸)벤질옥시-3-(S)-페닐-4(4-이미다졸로)메틸-모르폴린; 172) 2-(S)-(2-플루오로-5-트리플로오로메틸)벤질옥시-3-(S)-(4-플루오로)페닐-4-(4-이미다졸로)메틸-모르폴린; 173) 2-(R)-(1-(R)-(2-플루오로-5-트리플루오로메틸)페닐에톡시)-3-(S)-페닐-4--(4-이미다졸로)메틸-모르폴린; 174) 2-(R)-(1-(R)-(2-플루오로-5-트리플루오로메틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-4(4-이미다졸로)메틸)-모르폴린; 175)2-(S)-(2-플루오로-5-트리플루오로메틸)벤질옥시-3-(S)-페닐-4-(5-테트라졸로)메틸-모르폴린; 176)2-(S)-(2-플루오로-5-트리플루오로메틸)벤질옥시-3-(S)-(4-플루오로)페닐-4-(5-테트라졸로)메틸-모르플린; 177) 2-(R)-(1-(R)-(2-플루오로-5-트리플루오로메틸)페닐에톡시)-3-(S)-페닐-4-(5-테트라졸로)메틸-모르폴린; 178) 2-(R)-(1-(R)-(2-플루오로-5-트리플루오로메틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(5-테트라졸로)메틸-모르폴린; 179)2-(S)-(2-플루오로-5-트리플루오로메틸)벤질옥시-3-(S)-페닐-4-(2-옥소-5H-피롤-4-일)메틸-모르폴린; 180) 2-(S)-(2-플루오로-5-트리플루오로메틸)벤질옥시-3-(S)-(4-플루오로)페닐-4-(2-옥소-5G-피롤-4-일)메틸-모르폴린; 181) 2-(R)-(1-(R)-(2-플루오로-5-트리플루오로메틸)페닐에톡시)-3-(S)-페닐-4-(2-옥소-5H)-피롤-4-일)메틸-모르폴린; 182) 2-(R)-(1-(R)-(2-플루오로-5-트리플루오로메틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(2-옥소-5H-피롤-4-일)메틸-모르폴린; 183)2-(S)-(2-클로로-5-트리플루오로메틸)벤질옥시-3-(S)-페닐-모르폴린; 184) 2-(S)-(2-크로로-5-트리플루오로메틸)벤질옥시-3-(S)-(4-플루오로페닐-모르폴린; 185)2-(R)-(1-(R)-2(-클로로-5-트리플루오로메틸)페닐옥시-3-(S)-(4-플루오로)페닐-모르폴린; 186) 2-(R)-(1-(R)-(2-클로로-5-트리플루오로메틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-모르폴린; 187)2-(S)-(2-클로로-5-트리플루오로메틸)벤질옥시-3-(S)-페닐-4-(3-(1,2,4-트리아졸로)메틸-모르폴린; 188) 2-(S)-(2-클로로-5-트리플루오로메틸)벤질옥시-3-(S)-(4-플루오로)페닐-4-(3-(1,2,4-트리아졸로)메틸-모르폴린; 189)2-(R)-(1-(R)-(2-클로로-5-트리플루오로메틸)페닐에톡시)-3-(S)-페닐-4-(3-(1,2,4트리아졸로)메틸-모르폴린; 190) 2-(R)-(1-(R)-(2-클로로-5-트리플루오로메틸)페닐에톡시)-3-(S) -(4-플루오로)페닐-4-(3-(1,2,4-트리아졸로)메틸-모르폴린; 191) 2-(S)-(2-클로로-5-트리플루오로메틸)벤질옥시-3-(S)-페닐-4-(3-(5-옥소-1H,4H, -1,2,4-트리아졸로)메틸)-모르폴린; 192)2-(S)-(2-클로로-5-틀플루오로메틸)벤질옥시-3-(S)-(4-플루오로페닐)-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 193)2-(R)-(2-클로로-5-트리플루오로메틸)페닐에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 194) 2-(R)-(1-(R)-(2-클로로-5-트리플루오로메틸페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(4-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 195) 2-(S)-(2-클로로-5-트리플루오로메틸)벤질옥시-3-(S)-페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 196) 2-(S)-(2-클로로-5-트리플루오로메틸)벤질옥시-3-(S)-(4-플루오로페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린 197) 2-(R)-(1-(R)-(2-클로로-5-트리플루오로메틸)페닐에톡시)-3-(S)-페닐-4(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 198) 2-(R)-(1-(R)-(2-클로로-5-트리플루오로메틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-4(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 199) 2-(S)-(2-클로로-5-트리플루오로메틸)벤질옥시-3-(S)-페닐-4-(2-이미다졸로)페닐-모르폴린; 200) 2-(S)-(2-클로로-5-트리플루오로메틸)벤질옥시-3-(S)-(4-플루오로페닐)-4(2-이미다졸로)페닐-모르폴린; 201)2-(R)-(1-(R)-(2-클로로-5-트리플루오로메틸)페닐에톡시)-3-(S)-페닐-4-이미다졸로)메틸)-모르폴린; 202) 2-(R)-(1-(R)-(2-클로로-5-트리플루오로메틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(2-이미다졸로)메틸)-모르폴린; 203) 2-(S)-(2-클로로-5-트리플루오로메틸)벤질옥시-3-(S)-(4-플루오로페닐-4-(4-이미다졸로)메틸-모르폴린; 205) 2-(R)-(1-R)-2-클로로-5-트리플루오로메틸)페닐에톡시)-3-(S)페닐-4-(4-이미다졸로)메틸-모르폴린; 206) 2-(R)-(1-(R)-(2-클로로-5-트리플루 오로메틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(4-이미다졸로)메틸-모르폴린; 207) 2-(S)-(2-클로로-5-트리플루오로메틸)벤질옥시-3-(S)-페닐-4-)5-테트라졸로)메틸-모르폴린; 208) 2-(S)-(2-클로로-5-트리플루오로메틸)벤질옥시-3-(S)-(4-플루오로)페닐-4-(5-테트라졸로)메틸-모르폴린; 209) 2-(R)-(1-(R)-(2-클로로-5-트리플루오로메틸)페닐에톡시)-3-(S)-페닐-4-(5-테트라졸로)메틸-모르폴린; 210) 2-(R)-(1-(R)-(2-클로로-5-트리플루오로메틸)페닐에톡시)-3-(S)-(4-플루올)페닐-4-(5-테트라졸로)메틸-모르폴린; 211) 2-(S)-(2-클로로-5-트리플루오로메틸)벤질옥시-3-(S)-페닐-4-(2-옥소-5H-피롤-4-일)메틸-모르폴린; 212) 2-(S)-(2-클로로-5-트리플루오로메틸)벤질옥시-3-(S)-(4-플루오로페닐-4-(2-옥소-5H-피롤-4-일)메틸-모르폴린; 213)2-(R)-(1-(R)-(2-클로로-5-트리플루오로메틸)페닐에톡시)-3-(S)-페닐-4-(2-옥소-5H-피롤-4-일)메틸-모르폴린; 214) 2-(R)-(1-(R)-(2-클로로-5-트리플루오로메틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(2-옥소-5H-피롤-4-일)메틸-모르폴린; 215) 2-(S)-(3-메틸)벤질옥시-3-(S)-페닐-모르폴린; 216) 2-(S)-(3-메틸)벤질옥시-3-(S)-(4-플루오로)페닐-모르폴린; 217)2-(R)-(1-(R)-(3-메틸)페닐에톡시)-3-(S)-페닐-모르폴린; 218) 2-(R)-(1-(R)-(3-메틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-모르폴린; 219) 2-(S)-(3-메틸벤질옥시-3-(S)-페닐-4-(3-(1,2,4-트라이졸로)메틸)-모르폴린; 220) 2-(S)-(3-메틸)벤질옥시-3-(S)-(4-플루오로)페닐-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 221)2-(R)-(1-(R)-(3-메틸)페닐에톡시)-3-(S)-페닐-4-(3-(1,2,3-트리아졸로)메틸)-모르폴린; 222) 2-(R)-(1-R)-(3-메틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1,2,4-트리아졸로)메틸-모르폴린; 225) 2-(R)-(1-(R)-(3-메틸)페닐에톡시)-3-(S)-페닐-4-(3-(4-옥소-1,2,4-트리아졸로)메틸-모르폴린; 226) 2-(R)-(1-(R)-(3-메틸)페닐에톡시)-3-(S)-4-플루오로)페닐-4-(3-(5-옥소-1,3,4-트리아졸로)메틸)-모르폴린; 228)2-(S)-(3-메틸벤질옥시-3-(S)-페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 229) 2-(R)-(1-(R)-(3-메틸)페닐에톡시)-3-(S)-페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸-모르폴린; 230)2-(R)-(1-(R)-(3-메틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 231) 2-(S)-(3-메틸)벤질옥시-3(S)-페닐-4-(2-이미다졸로)메틸-모르폴린; 232) 2-(S)-(3-메틸)벤질옥시-3-(S)-(4-플루오로)페닐-4-(2-이미다졸로)메틸-모르폴린; 233) 2-(R)-(1-(R)-(3-메틸)페닐에톡시)-3-(S)-페닐-4-(2-이미다졸로)메틸-모르폴린; 234) 2-(R)-(1-(R)-(3-메틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(20이미다졸로)메틸-모르폴린; 235)2-(S)-(3-메틸)벤질옥시-3-(S)-페닐-4-(4-이미다졸로)메틸-모르폴린; 236) 2-(S)-(3-메틸)벤질옥시-3-(S)-(4-플루오로)-페닐-4-(4-이미다졸로)메틸-모르폴린; 237) 2-(R)-1(-(R)-3(3-메틸)페닐에톡시)-3-(S)-페닐-4-(4-이미다졸로)메틸-모르폴린; 238_ 2-(R)-(1-(S)-(3-메틸)페닐에톡시)-3(S)-(4-플루오로)페닐-4-(4-이미다졸로)메틸-모르폴린; 239)2-(S)-(3-메틸)벤질옥시-3-(S)-페닐-4-(5-테트라졸로)메틸-모르폴린; 240) 2-(S)-(3-메틸)벤질옥시-3-(S)-(4-플루오로)페닐-4-(5-테트라졸로)메틸-모르폴린; 241) 2-(R)-(1-(R)-(3-메틸)페닐에톡시)-3-(S)-페닐-4-(5-테트라졸로)메틸-모르폴린; 242) 2-(R)-(1-(R)-(3-메틸)페닐에톡시)-3(S)-(4-플루오로)페닐-4-(5-테트라졸로)메틸-모르폴린; 243) 2-(S)-3-메틸)벤질옥시-3-(S)-페닐-4-(2-옥소-5H-피롤-4-일)메틸-모르폴린; 244)2-(S)-(3-메틸)벤질옥시-3-(S)-(4-플루오로)페닐-4-(2-옥소-5H-필ㄹ-4-일)메틸-모르폴린; 245) 2-(R)-(1-(R)-(3-메틸)페닐에톡시)-3-(S)-페닐-4-(2-옥소-5H-피롤-4-일)메틸-모르폴린; 246) 2-(R)-(1-(R)-(3-메틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(2-옥소-5ㅗ-피롤-4-일)메틸-모르폴린; 247) 2-(S)-(3-브로모)벤질옥시-3-(S)-페닐-모르폴린; 248) 2-(S)-(3-브로모)벤질옥시-3-(S)-(4-플루오로)페닐-모르폴린; 249)2-(R)-(1-(R)-(3-브로모)페닐에톡시-3-(S)-페닐-모르폴린; 250) 2-(R)-(1-(R)-(3-브로모)페닐에톡시)-3-(S)-(4-플루오로)페닐-모르폴린; 251)2-(S)-(3-브로모)벤질옥시-3-(S)-패닐-4-(3-(1,2,4-트리아졸로)메틸-모르폴린; 252) 2-(S)-(3-브로모)벤질옥사-3-(S)-(4-플루오로)페닐-4-(3-1,2,4-트리아졸로)메틸-모르폴린; 253) 2-(R)-(1-(R)-(3-브로모)페닐에톡시)-3-(S)-페닐-4-(3-(1,2,4-트리아졸로)메틸-모르폴린; 254)2-(R)-(1-(R)-(3-브로모)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(1,2,4-트리아졸로)메틸-모르폴린; 255)2-(S)-3-브로모)벤질옥시-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸-모르폴린; 256) 2-(S)-(3-브로모)벤질옥시-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸-모르폴린; 257) 2-(R)-(1-(R)-(3-브로모)페닐에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 258) 2-(R)-(1-(R)-(3-브로모)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 259) 2-(S)-(3-브로모)-벤질옥시-3-(S)-페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 260) 2-(S)-(3-브로모)벤질옥시-3-(S)-(4-플루오로)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 261) 2-(R)-(1-(R)-(3-브로모)페닐에톡시)-3-(S)-페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 262) 2-(R)-(1-(R)-(3-브로모)페닐에톡시)-3-(S)-(4-블루오로)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 263) 2-(S)-(3-브로모)벤질옥시-3-(S)-페닐-4-(2-이미다졸로)메틸-모르폴린; 264)2-(S)-(3-브로모)벤질옥시-3-(S)-(4-플루오로)페닐-4-(2-이미다졸로)메틸-모르폴린; 265)2-(R)-(1-(R)-(3-브로모)페닐에톡시)-3(S)-페닐-4-(2-이미다졸로)메틸-모르폴린; 266)2-(R)-(1-(R)-(3-브로모)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(2-이미다졸로)메틸-모르폴린; 267) 2-(S)-(3-브로모)벤질옥시-3-(S)-(4-플루오로)페닐-4-(2-이미다졸로)메틸-모르폴(3-브로모)벤질옥시-3-(S)-페닐-4-(5-테트라졸로)메틸-모르폴린; 272) 2-(S)-(3-브로모)벤질옥시-3-(S)-(4-플루오로)페닐-4-(5-테트라졸로)메틸-모르폴린; 274) 2-(R)-(1-(R)-(3-브로모)페닐에톡시)-3-(S)-페닐-4-(5-테트라졸로)메틸-모르폴린; 274)2-(R)-(1-(R)-(3-브로모)페닐엑톡시)-3(S)-(4-플루오로)페닐-4-(5-테트라졸로)메틸-모르폴린;275) 2-(S)-(3-브로모)벤질옥시-3-(S)-페닐-4-(2-옥소-5H-피를-4-일)메틸-모르폴린; 276) 2-(S)-(3-브로모)벤질옥시-3-(S)-(4-플루오로)페닐-4-(2-옥소-5H-피룰-4-일)메틸-모르폴린; 277) 2-(R)-(1-(R)-(3-브로모)페닐에톡시)-3-(S)-페닐-4-(2-옥소-5H-피룰-4-일)메틸-모르폴린; 278) 2-(R)-(1-(R)-(3-브로모)페닐에톡시)-3-(S)-(4-플루오로)패널-4-(2-옥소-5H-피룰-4-일)메틸-모르폴린; 279) 2-(S)-(3-클로로)벤질옥시-3-(S)-패닐-모르폴린; 280) 2-(S)-(3-클로로)벤질옥시-3-(S)-(4-플루오로)페닐-모르풀린; 281) 2-(R)-(1-(R)-(3-클로로)페닐에톡시)-3(S)-페닐-모르폴린; 282) 2-(R)-(1-(R)-(3-클로로)페닐에톡시)-3-(S)-(4-플루오로)페닐-모르폴린; 283) 2-(S)-(3-클로로)벤질옥시-3-(S)-페닐-4-(3-(1,2,4-트리아졸로)메틸)-모르폴리; 284) 2-(S)-(3-클로로)벤질옥시-3-(S)-(4-플루오로)페닐-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 285) 2-(R)-(1-(R)-(2-클로로)페닐에톡시)-3-(S)-페닐-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 286) 2-(R)-(1-(R)-(3-클로로)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 287) 2-(S)-(3-클로로)벤질옥시-3-(S)-페널-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 288) 2-(S)-(3-클로로)벤질옥시-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H12,3,4-트리아졸로)메틸)-모르폴린; 289) 2-(R)-(1-(R)-(3-클로로)페닐에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 290) 2-(R)-(1-(R)-(3-클로로)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린;291) 2-(S)-(3-클로로)벤질옥시-3-(S)-페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린;모르폴린; 292) 2-(S)-(3-클로로)벤질옥시-3-(S)-(4-플루오로)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 293) 2-(R)-(1-(R)-(3-클로로)페닐에톡시)-3-(S)-페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 294) 2-(R)-(1-(R)-(3-클로로)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-몰폴린; 295) 2-(S)-(3-클로로)벤질옥시-3-(S)-페닐-4-(2-이미다졸로)메틸-모르폴린; 296)2-(S)-(3-클로로)벤질옥시-3-(S)-(4-플루오로)페닐-4-(2-이미다졸로)메틸-모르폴린; 297) 2-(R)-(1-(R)-(3-클로로)페닐에토ㄷ시)-3-(S)-페닐-4-(2-이미다졸로)메틸-모르폴린; 298) 2-(R)-(1-(R)-(3-클로로)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(2-이미다졸로)메틸-모르폴린;299)2-(S)-(3-클로로)벤질옥시-3-(S)-페닐-4-(4-이미다졸로)메틸-모르폴린; 300) 2-(S)-(3-클로로)벤질옥시-3-(S)-(4-플루오로)페닐-4-(4-이미다졸로)메틸-모르폴린; 301) 2-(R)-(1-(R)-(30클로로)-페닐에톡시)-3-(S)-페닐-4-(4-이미다졸로)메틸-모르폴린; 302) 2-(R)-(1-(R)-(3-클로로)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(4-이미다졸로(메틸-모르폴린; 303) 2-(S)-(3-클로로)-벤질옥시-3-(S)-페닐-4-(5-테트라졸로)메틸-모르폴린; 304_ 2-(S)-(3-클로로)벤질옥시-3-(S)-(4-플루오로)페닐-4-(5-테트라졸로)메틸-모르폴린;305) 2-(R)-(1-(R)-(3-클로로)페닐에톡시)-3-(S)-페닐-4-(5-테트라졸로)메틸-모르폴린; 306)2-(R)-(1-(R)-(3-클로로)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(5-테트라졸로)메틸-모르폴린; 307) 2-(S)-(3-클로로)벤질옥시-3-(S)-페닐-4-(2-옥소-5H-피롤-4-일)메틸-모르폴린;308) 2-(S)-(3-클로로)벤질옥시-3-(S)-(4-플루오로)페닐-4-(2-옥소-5H-피롤-4-일)메틸-모르폴린; 309) 2-(R)-(1-(R)-(3-클로로)페닐에톡시)-3-(S)-페닐-4-(2-옥소-5H-필ㄹ-4-일)메틸-모르폴린;310)2-(R)-(1-(R)-(3-클로로)페닐에톡시)-3-(S)-(4-플루오로)페닐)-4-(2-옥소-5H-피롤-4-일)메틸)-모르폴린; 311) 2-(R)-(3-트리플루오로메틸)벤질옥시-3-(S)-페닐-모르폴린; 312)2-(S)-(3-트리플루오로메틸)벤질옥시-3-(S)-(4-플루오로)페닐-모르폴린; 313) 2-(R)-(-()-(3-트리플루오로메틸)페닐에톡시)-3-(S)-페닐-모르폴린; 314) 2-(R)-(1-(R)-(3-트리플루오로메틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-모르폴린;315) 2-(S)-(3-트리플루오로메틸)벤질옥시-3-(S)-4-플루오로)페닐-4-(3-1H,4H-1,2,4트리아졸로)메틸-모르폴린; 317) 2-(R)-(1-(R)-(3-트리플루오로메틸)페닐에톡시)-3-(S)-페널-4-(3-1H,4H-1,2,3-트리아절로)메틸-모르폴린; 318) 2-(R)-(2-(R)-(3-트리플루오로메틸)페닐에톡시)-(S)-(4-플루오로)페닐-4-(3-(1,2,4-트리아졸로)메틸-모르폴린; 319) 2-(S)-(3-트리플루오로메틸)벤질옥시-3-(S)-페닐-4-(3-(5-옥소)-1H,4H-1,2,4-1,2,4-트리아졸로)메틸-모르폴린; 320) 2-(S)-(3-트리플루오로메틸)벤질옥시-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸-모르폴린; 321) 2-(R)-(1-(R)-(3-트리플루오로메틸)페닐에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 322)2-(R)-(1-(R)-(3-트리플루오로메틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 323) 2-(S)-(3-트리플루오로메틸)벤질옥시-3-(S)-페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 324) 2-(S)-(3-트리플루오로메틸)벤질옥시-3-(S)-(4-플루오로)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린;325)2-(R)-(1-(R)-(3-트리플루오로메틸)페닐에톡시)-3-(S)-페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 326) 2-(R)-(1-(R)-(3-트리플루오로메틸)페닐에톡시)-3-(S)-94-플루오로)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 327) 2-(S)-(3-트리플루오로메틸)벤질옥시)-3-(S)-페닐-4-(2-이미다졸로)메틸-모르폴린; 328) 2-(S)-(3-트리플루오로메틸)벤질옥시-3-(S)-(4-플루오로)페닐-4-(2-이미다졸로)메틸-모르폴린; 329)2-(R)-(1-(R)-(3-트리플루오로메틸)페닐에톡시)-3-(S)-페닐-4-(-이미다졸로)메틸-모르폴린; 330)2-(R)-(1-(R)-(3-트리플루오로메틸)페닐에톡시)-3-(S)-(4-플루오로-페닐-4-(2-이미다졸로)메틸-모르폴린; 331)2-(S)-(3-트리플루오로메틸)벤질옥시-3-(S)-페닐-4-(4-이미다졸로)메틸-모르폴린;332) 2-(S)-(3-트리플루오로메틸)벤질옥시-3-(S)-(4-플루오로)페틸-4-(4-이미다졸로)메틸-모르폴린; 333) 2-(R)-(1-(R)-(3-트리플루오로메틸)페닐에톡시)-3-(S)-페닐-4-(4-이미다졸로)메틸-모르폴린; 334) 2-(R)-(1-(R)-(3-트리플루오로메틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(4-이미다졸릴)메틸-모르폴린; 335) 2-(S)-(3-트리플루오로메틸)벤질옥시-3-(S)-페닐-4-(5-테트라졸로)메틸-모르폴린;336) 2-(S)-(3-트리플루오로메틸)벤질옥시-3-(S)-(4-플루오로)페닐-4-(5-테트라졸로)메틸-모르폴린; 337) 2-(R)-(1-(R)-(3-트리플루오로메틸)페닐에톡시)-3-(S)-페닐-4-(5-테트라졸로)메틸-모르폴린; 338) 2-(R)-(1-(R)-(3-트리플루오로메틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(5-테트라졸로)메틸-모르폴린; 339) 2-(R)-(3-트리플루오로메틸)벤질옥시-3-(S)-페닐--(2-옥소-5H-피롤-4-일)메틸-모르폴린; 340) 2-(S)-(3-트리플루오로메틸)벤질옥시-3-(S)-(4-플루오로)페닐-4-(2-옥소-5H-피롤-4-일)메틸-모르폴린;341)2-(R)-(1-(R)-(3-트리풀루오로메틸)페닐에톡시)-3-(S)-페닐-4-(2-옥소-5H-피롤-4-일)메틸-모르폴린; 342) -(R)-(1-(R)-(3-트리플루오로메틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(2-옥소-5H-피롤-4-일)메틸-모르폴린343) 2-(S)-(3-t-부틸)페닐에톡시)-3-(S)-페닐-모르폴린; 344) 2-(S)-(3-t-부틸)벤질옥시-3-(S)-(4-플루오로)페닐-모르폴린; 345) 2-(R)-(1-(R)-(3-t-부틸)페닐에톡시)-3-(S)-페닐-모르폴린; 346) 2-(R)-(1-(R)-(3-t-부틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-모르폴린; 347; 2-(S)-(3-t-부틸)벤질옥시-3-(S)-페닐-4-(3-(1,2,4-트리아졸로(메틸)-모르폴린; 348) 2-(S)-(3-t0부틸)벤질옥시-3-(S)-(4-플루오로)페닐-4-(3-(1,2,4-트리아졸로)메틸-모르폴린; 349)2-(R)-(1-(R)-(3-t-부틸)페닐에톡시)-3-(S)-페닐-4-(3-1,2,4-트리아졸로)메틸)-모르폴린; 350) 2-(R)-(1-(R)-(3-t-부틸(페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(1,2,4-트리아졸로)메틸-모르풀린; 351) 2-(S)(3-t-부틸)벤질옥시-3-(S)-패닐-4-(3-(5-옥소-1H,4H-1,2,4트리아졸로)메틸-모르폴린; 352) 2-(S)-(3-t-부틸)벤질옥시-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메티-모르폴린;.353) 2-(R)-(1-(R)-(3-t-부틸)페닐에톡시)3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸-모르폴린; 354) 2-(R)-(1-(R)-(3-t-부틸)페닐에톡시)-3-(S)-(4--플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-드리아졸로)메틸-모르폴린; 355) 2-(S)-(3-t-부틸)벤젤옥시-3-(S)-페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸-모르폴린; 356)2-(S)-(3-t-부틸)벤젤옥시-3-(S)-(4-플루오로)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸-모르풀린; 357)2-(R)-(1-(R)-(3-t-부틸)페닐에톡시)-3-(S)-페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸-모르폴린; 358) 2-(R)-(1-(R)-(3-t-부틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸-모르폴린; 359) 2-(S)-(3-t-부틸)벤질옥시-3-(S)-페닐-4-(2-이미다졸로)메틸-모르폴린; 360) 2-(S)-(3-t-부틸)벤질옥시-3-(S)-(4-플루오로)페닐-4-(2-이미다졸로)메틸-모르풀린; 361) 2-(R)-(1-(R)-(3-t-부틸)페닐에톡시)-3-(S)-페닐-4-(2-이미다졸로)메틸-모르폴린;362) 2-(R)-(1-(R)-(3-t-부틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(2-이미다졸로)메틸-모르폴린; 363) 2-(S)-(3-t-부틸)벤질옥시-3-(S)-페닐-4-(4-이미다졸로)메틸-모르폴린; 364)2-(S)-(3-t-뷜)페닐에톡시)-3-(S)-4-플루오로)페닐-4-(4-이미다졸로)메틸-모르폴린; 365) 2-(S)-(1-(R)-(3-t부틸)페닐에톡시)-3-(S)페닐-4-(4-이미다졸로)-메틸-모르폴린; 366)2-(R)-(1-(R)-(3-t-부틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(4-이미다졸릴)메틸-모르폴린; 367)2-(S)-(3-1부틸)벤질옥시-3-(S)-페닐-4-(5-테트라졸로)메틸-모르폴린; 368) 2-(S)-(3-t-부틸)벤질옥시-3-(S)-(4-플루오로)페닐-4-(5-테트라졸로)메틸-모르폴린; 369) 2-(R)-(1-(R)-(3-t-부틸)페닐에톡시)-3-(S)-페닐-4-(5-테트라졸로)메틸-모르폴린; 370) 2-(R)-(1-(R)-(3-t-부틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(5-테트라졸로)메틸-모르폴린; 371) 2-(S)-(3-t-부틸)벤젤옥시-3-(S)-페닐-4-(2-옥소-5H-피롤-4-일)메틸-모르폴린; 372) 2-(S)0(3-t-부틸)벤질옥시-3-(S)-(4-플루오로)페닐-4-(2-옥소-5H-피롤-4-일)메틸-모르폴린; 373) 2-(R)-(1-(R)-(3-t-부틸)페닐에톡시)-3-(S)-페닐-4-(2-옥소-5H-피롤-4-일)메틸-모르플린; 374) 2-(R)-(1-(R)-(3-t-부틸)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(2-옥소-5H-피롤-4-일)메틸-모르폴린; 375) 4-(4-(이미다졸로)메틸)-2-(3-(t-부틸)-5-(트리플루오로메틸)-벤질옥시)-3-페닐-모르폴린; 376) 2-(R)-(2,5-비스(트리플루오로메틸)벤조일옥시)-3-(S)-(4-플루오로페닐)-4벤질-모르폴린; 377) 2-(R)-(1-(2,5-비스(트리플루오로메틸)페닐)에테닐옥시)-3-(S)-(4-플루오로페닐)-4-벤질-모르폴린; 378) 2-(R)-(1-(R)-(2,5-비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(4-플루오로페닐)-모르폴린; 379) 2-(R)-(1-(R)-(2,5-비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(4-플루오로페닐)-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸-모르폴린; 380) 2-(R)-(1-(R)-(2,5-비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(4-플루오로페닐)-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 381) 2-(R)-(1-(R)-(2,5-비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(4-플루오로페닐)-4-(4-(2-옥소-1,3-이미다졸로)메틸-모르폴린; 382) 2-(R)-(1-(R)-(3-(티오메틸)페닐)에톡시)-3-(S)-페닐-모르폴린; 383) 2-(R)-(1-(R)-(3-(티오메틸페닐)에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 384) 2-(R)-(1-(R)-(3-(티오메틸페닐)에톡시)-3-(S)-페닐-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 385) 2-(R)-(1-(R)-(3-(티오메틸페닐)에톡시)-3-(S)-페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 386) 2-(R)-(1-(R)-(3-(티오메틸)-5-(트리플루오로메틸)페닐)에톡시)-3-(S)-페닐-모르폴린; 387) 2-(R)-(1-(R)-(3-(티오메틸)-55-(트리플루오로메틸)페닐)에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 388) 2-(R)-1-(R)-(3-(티오메틸)-5-(트리플루오로메틸)페닐)에톡시-3-(S)-페닐-4-(3-91,2,4-트리아졸로)메틸)-모르폴린; 389) 2-(R)-(1-(R)-(3(티오메틸)-5-(트리플루오로메틸)페닐)에톡시)-3-(S)-페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 390) 2-(R)-(1-(R)-(2,2-디메틸)-5-(티오메틸)-2,3-디히드로벤조푸란-7-일)에톡시)-3-(S)-페닐-모르폴린; 391) 2-(R)-(1-(R)-(2,2-디메틸)-5-(티오메틸)-2,3-디히드로벤조푸란-7-일)에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)모르폴린; 392) 2-(R)-(1-(R)-(3.5-(디메톡시)페닐)에톡시)-3-(S)-페닐-모르폴린; 395) 2-(R)-(1-(R)-(3,5-(디메톡시)페닐)에톡시)--(S)-페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 396) 2-(R)-(1-(R)-(3,5-(디메톡시)페닐)에톡시)-3-(S)-페닐-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 397) 2-(R)-(1-(R)-(3,5-(디메톡시)페닐)에톡시)-3-(S)-페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르풀린; 398) 2-(R)-(1-(R)-(3-(플루오로)-5-(트리플루오로메틸)페닐)-에톡시)-3-(S)-(4-플루오로페닐)-모르폴린; 399) 2-(R)-(10(R)-(3-(플루오로페닐)-5-(트리플루오로메틸)에톡시)-3-(S)-(4-플루오로페닐)-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 400) 2-(R)1-(R))-(3-(플루오로페닐)-5-(트리플루오로메틸)에톡시)-3-(S)-(4-플루오로페닐)-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 401) 2-(R)-(1-(R)-(3-(플루오로페닐)-5-(트리플루오로메틸)에톡시)-3-(S)-(4-플루오로페닐)-4-(4-(2-옥소-1,3,-이미다졸로)메틸)-모르폴린; 402) 2-(R)-(1-(R)-(3-(클로로)-5-(트리플루오로메틸)페닐)-에톡시)-3-(S)-(4-플루오로페닐)-모르폴린; 403) 2-(R)-(1-(R)-(3-(클로로페닐)-5-(트리플루오로메틸)에톡시)-3-(S)-(4-플루오로)페닐)-4-(3-(5-옥소1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 404) 2-(R)-(1-(R)-3-(클로로페닐)-5-(트리플루오로메틸)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 405) 2-(R)-(1-(R)-(3-(클로로페닐)-5-(트리플루오로메틸)에톡시)-3-(S)-(4-플루오로)페닐)-4-(4-(2-옥소1,3-이미다졸로)메틸)-모르폴린; 406) 2-(R)-(1-(R)-(3,5-(디메틸)페닐)에톡시)-3-(S)-(4-플루오로)페닐)-모르폴린; 407) 2-(R)-(1-(R)-(3,5-(디메틸)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸-모르풀린; 408) 2-(R)-(1-(R)-(3,5-(디메틸)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 409) 2-(R)-(1-(R)-(3,5-(디메틸)-페닐)에톡시)-3-(S)-(4-플루오로)페닐)-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 410) 2-(R)-(1-(R)-(3-(플루오로)-5-(메틸)페닐)에톡시)-3-(S)-(4-플루오로)페닐-모르폴린; 411) 2-(R)-(1-(R)-(3-(플루오로)-5-(메틸)페닐)에톡시)-3-(S)-(4-플루오로)페닐)-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 412) 2-(R)-(1-(R)-(3-플루오로)-5-(메틸)페닐)에톡시)-3-(S)-(4-플루오로)페닐)-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 413) 2-(R)-(1-(R)-(3-(플루오로)-5-(메틸)-페닐)에톡시)-3-(S)-(4-플루오로)페닐)-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 414) 2-(R)-(1-(R)-(3-(클로로)-5-(메틸)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸-모르폴린; 416) 2-(R)-(1-(R)-(3(클로로)-5-(메틸)페닐)에토기)-3-(S)-(4-플루오로)페닐)-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 417) 2-(R)-(1-(R)-(3-(클로로)-5-(메틸)페닐)에톡시)-3-(S)-(4-플루오로)패닐)-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린;418) 2-(R)-(1-(R)-(3-(R)-(3-(브로모)-5-(메틸)페닐)에톡시)-3-(S)-(-4-플루오로)페닐-모르폴린;419) 2-(R)-(1-(R)-(3-(R)-(3-(브로모)-5-(메틸)페닐)에톡시)-3-(S)-(-4-플루오로)페닐-4-(3-5-옥소-1H,4H-1,2,4-트라이아졸로)메틸)-모르폴린; 420) 2-(R)-(1-(R)-(3-(브로모)-5-(메틸)패닐)에톡시)-3-(S)-(4-플루오로)페닐)-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 421) 2-(R)-(1-(R)-(3-(브로모)-5-(메틸)페닐)에톡시)-3-(S)-(4-플루오로)페닐)-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 422) 2-(R)-1(1-(R)-(3-(이소프로폭시)페닐)에톡시)-3-(S)-(4플루오로)페닐-모르폴린; 423) 2-(R)-(1-(R)-(3-(이소프로폭시)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 424) 2-(R)-(1-(R)-(3-이소프로폭시)페닐)에톡시)-3-(S)-(4-플루오로)페닐)-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 425) 2-(R)-(1-(R)-(3-(이소프로폭시)페닐)에톡시)-3-(S)-(4-플루오로)페닐)-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 426) 2-(R)-(1-(R)-(3-(이소프로폭시)-5-(트리플루오로메틸)페닐)에톡시)-3-(S)-(4-플루오로)페닐-모르폴린; 427) 2-(R)-(1-(R)-(3-(이소프로폭시)-5-(트리플루오로메틸)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 428) 2-(R)-(1-(R)-(3-(이소프로폭시)-5-(트리플루오로메틸)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 429) 2-(R)-(1-(R)-(3-(이소프로폭시)-5-(트리플루오로메틸)페닐)에톡시-3-(S)-(4-플루오로)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 430) 2-(R)-(1-(R)-(3-(클로로)-5-(이소프로폭시)페닐)에토시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 432) 2-(R)-(1-(R)-(3-(클로로)-5-(이소프로폭시)페닐)에톡시)-3-(S)-(4-플루오로)페닐)-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 433) 2-(R)-(1-(R)-(3-클로로)-5-(이소프로폭시)페닐)에톡시)-3-(S)-(4-플루으로)페닐)-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 434) 2-(R)-(1-(R)-(3-(플루오로)-5-(이소프로폭시)페닐)에톡시)-3-(S)-(4-플루오로)페닐-모르플린; 435) 2-(R)-(1-(R)-(3-(플루오로)-5-(이소프로폭시)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸-모르폴린; 436) 2-(R)-(1-(R)-(3-플루오로)-5-(이소프로폭시)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(1,2,4-트리아졸로)메틸-모르폴린; 437) 2-(R)-(1-(R)-(3-(플루오로)-5-(이소프로폭시)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(4-(2-옥소1,3-이미다졸로)메틸-모르폴린; 438) 2-(R)-(1-(R)-(3-(t-부틸)-5-(클로로)페닐)에톡시(-3-(S)-(4-플루오로)페닐-모르폴린; 439) 2-(R)-(1-(R)-(3-(t-부틸)-5-(클로로)페닐)에톡시(-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 440) 2-(R)-(1-(R)-(3-(t-부틸)-5-(클로로)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-1,2,4-트리아졸로)메틸)-모르폴린; 441)2-(R)-(1-(R)-(3-(t-부틸)-5-(클로로)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 442) 2-(R)-(1-(R)-(3-(t-부틸)-5-(트리플루오로메틸)페닐)에톡시)-3-(S)-(4-플루오로)페닐)-모르폴린; 443) 2-(R)-(1-(R)-3(t-부틸)-5-(트리플루오로메틸)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 444) 2-(R)-(1-(R)-(3-(t-부틸)-5-(트리플루오로메틸)페닐)에톡시)-3-(S)-(4-플루오로)페닐)-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 445)2-(R)-(1-(R)-(3-t-부틸)-5-(트리플루오로메틸)페닐)엑토시)-3-(S)-(4-플루오로)페닐)-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 446) 2-(R)-(1-(R)-(3,5-(디메틸)-4-(플루오로)페닐)에톡시)-3-(S)-(4-플루오로)페닐-모르폴린; 447) 2-(R)-(1-(R)-(3,5-(디메틸)-4(플루오로)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 448) 2-(R)-(1-(R)-(3,5-(디메틸)-4-(플루오로)페닐)에톡시)-3-(S)-(4-플루오로)페닐)-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 449) 2-(R)-(1-(R)-(3,5-(디메틸)-4-(플루오로)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 450)2-(R)-(1-(R)-(3,5-(디메틸)-4-(클로로)페닐)엑토시)-3-(S)-(4-플루오로)페닐)-모르폴린; 451) 2-(R)-(1-(R)-(3,5-(디메틸)-4-(클로로)페닐)엑토시)-3-(S)-(4-플루오로)페닐)-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 452) 2-(R)-(1-(R)-(3,5(디메틸)-4-(클로로)페닐)엑톡시)-3-(S)-(4-플루오로)페닐)-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 453) 2-(R)-(1-(R)-(3,5)-디메틸)-4-(클로로)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 454) 2-(R)-(1-(R)-(3,5-비스(트리플루오로메틸)-4-(플루오로)페닐)에톡시-3-(S)-(4-플루오로)페닐)-모르폴린; 455) 2-(R)-(1-(R)-(3,5-비스(트리플루오로메틸)-4-(플루오로0페닐)에톡시)-3-(S)-4-플루오로)페닐-4-(3-5(-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 456) 2-(R)-(1-(R)-(3,5-비스(트리플루오로메틸)-4-(플루오로)페닐)에톡시)-3-(S)-(4-플루오로)페닐)-4-(301,2,4-트리아졸로)메틸-모르폴린; 457) 2-(R)-(1-(R)-(3,5-비스(트리플루오로메틸)-4-(플루오로)페닐-에톡시)-3-(S)-(4-플루오로)페닐)-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린 458) 2-(R)-(1-(R)-(3,5-비스(트리플루오로메틸)-4-(클로로)페닐)에톡시)-3-(S-(4-플루오로)페닐-모르폴린;495) 2-(R)-(1-(R)-(3,5-비스(트리플루오로메틸)-4-(클로로)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 460( 2-(R)-(1-(R)-(3,5-비스(트리플루오로메틸)-4-(클로로)페닐)에톡시-3-(S)-(4-플루오로)페닐-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 461) 2-(R)-(1-(R)-(3,5-비스(트리플루오로메틸)-4-(클로로)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 462) 2-(R)-(1-(R)-(3,5-(디클로로)페닐)에톡시)-3-(S)-(4-플루오로)페닐-모르폴린; 463) 2-(R)-(1-(R)-(3,5-(디클로로)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 464) 2-(R)-(1-(R)-(3,5-(디클로로)페닐)엑토시)-3-(S)-(4-플루오로)페닐-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 465) 2-(R)-(1-(R)-(3,5(-디클로로)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 466)2-(R)-(1-(R)-(3,5-(디플루오로)페닐)에톡시)-3-(S)-(4-플루오로)페닐-모르폴린; 467)2-(R)-(1-(R)-(3,5-(디플루오로)페닐)에톡시)-3-(S)-(4-플루오로)페닐4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모프폴린; 468)2-(R)-(1-(R)-(3,5-(디플루오로)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 469)2-(R)-(1-(R)-(3,5-(디플루오로)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 470) 2-(R)-(1-(R)-(1-(나프틸)에톡시)-3-(S)-(4-플루오로)페닐-모르폴린; 471) 2-(R)-(1-(R)-(1-(나플틸)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸-모르폴린; 472) 2-(R)-(1-(R)-(1-(나프틸)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(1,2,4-트리아졸로)메틸-모르폴린; 473) 2-(R)-(1-(R)-(10(나프틸)에톡시)-3-(S)-(4-플루오로)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린;474) 2-(R)-(1-(R)-(1-(4-(플루오로)나프틸)0에톡시)-3-(S)-(4-플루오로)페닐-모르폴린; 475) 2-(R)-(1-(R)-(1-(4-(플루오로)나프틸))에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 476) 2-(R)-(1-(R)-(1-(4-(플루오로)나프틸))에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(1,2,4-트리아졸로)메틸)-모르폴리; 477) 2-(R)-(1-(R)-(1-(4-(플루오로)나프틸))에톡시)-3-(S)-(4-플루오로)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸-모르폴린; 478) 2--(R)-(1-R)-(1-(3-(플루오로)나프틸))에톡실)-3-3(S)-(4-플루오로)페닐-모르폴린; 479) 2-(R)-(1-(R)-(1-(3-(플로오로)나프틸)-엑톡시)-3-(S)-(4-플루오로)페닐-4-(3-5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 480) 2-(R)-(1-(R)-(1-(3-(플루오로)나프틸))에톡시)-3-(S)-(4-플루오로)페닐)-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 481) 2-(R)-(1-(R)-(1-(3-(플루오로(나프틸))에톡시)-3-(S)-(4-풀루오로)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 482) 2-(R)-(1-(R)-(1-(3-(클로로)나프틸))에톡시)-3-(S)-(4-플루오로)페닐-모르폴린; 483) 2-(R)-(1-(R)-(1-3-(클로로)나프틸))에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-틀리아졸로)메틸)-모르폴린; 484) 2-(R)-(1-(R)-(1-(3-(클로로)나프틸))에톡시)-3-(S)-(4-플루오로)페닐)-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 485) 2-(R)-(1-(R)-(1-(3-(클로로)나프틸))에톡시)-3-(S)-(4-플루오로)페닐)-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 486) 2-(R)-(1-(R)-(1-(3-(메틸)나프틸))에톡시)-3-(S)-(4-플루오로)페닐-모르폴린; 487) 2-(R)-(1-(R)-1(10(30(메틸)나프틸))에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 488)2-(R)-(1-(R)-(1-(3-(메틸)나프틸))에톡시)-3-(S)-(4-플루오로)페닐)-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 489)2-(R)-(1-(R)-(1-3-(메틸)나프틸))에톡시)-3-(S)-(4-플루오로)페닐)-4-(4-(2-옥소-1,3-이미다졸)메틸)-모르폴린; 490) 2-(R)-(1-(R)-(1-(3-(트리플루오로메틸)나프틸))에톡시)-3-(S)-(4-플루오로)페닐-모르폴린; 491) 2-(R)-(1-(R)-(10(3-(트리플루오로메틸)나프틸))에톡시)-3-(S)_(4-플루오로)페닐-4-(3-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 492) 2-(R)-(1-(R)-(1-(3-(트리플루오로메틸)나프틸))에톡시)-3-(S)-(S)-4-플루오로)페닐)-4(30(1,2,4-트리아졸로)메틸)-모르폴린; 493) 2-(R)-(1-(R)-(1-(3-(트리플루오로메틸)나프틸))에톡시)-3-(S)-(40플루오로)페닐)-4-(4-(20옥소-1,3-이미다졸로)메틸)-모르폴린; 495) 2-(R)-(1-(R)-(3-(티오메틸)페닐)에톡시)-3-(S)-(4-플루오로)페닐-모르폴린; 495)2-(R)-(1-(R)-(3-(티오메틸)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸)-모르폴린; 496) 2-(R)-(1-(R)-(3-(티오메틸페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 497)2-(R)-(1-(R)-(3-티오메틸페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 498) 2-(R)-(1-(R)-(3-(티오메틸)-5-(트리플루오로메틸)페닐)에톡시)-3-(S)-(4-플루오로)페닐-모르폴린; 499)2-(R)-(1-(R)-(3-(티오메틸-5-(트리플루오로메틸)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H,4H-1,2,4-트리아졸로)메틸-모르폴린; 500) 2-(R)-(1-(R)-(3-(티오메틸5-(트리플루오로메틸)페닐)에톡시)-3-(S)-(4-플루오로)페닐)-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 501)2-(R)-(1-(R)-(3-티오메틸-5-(트리플루오로메틸)페닐)에톡시)-3-(S)-(4-플루오로)페닐)-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 502) 2-(R)-(1-(R)-(2,3-(디메틸-5-(티오메틸)-2,3-디히드로-벤조푸란-7-일)에톡시0-3-(S)-(4-플루오로)페닐-모르폴린; 503)2-(R)-(1-(R)-(2,2-(디메틸)-5-(티오메틸-2,3-디히드로-벤조푸란-7-일)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H, 4H-1, 2, 4-트리아졸로)메틸-모르폴린; 504) 2-(R)-(1-(R)-(2, 2-(디메틸)-5-(티오메틸)-2, 3-디히드로-벤조푸란-7-일)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(1, 2, 4-트라이졸로)메틸)-모르폴린; 505) 2-(R)-(1-(R)-(2,2-(디메틸)-5-(티오메닐)-2, 3-디히드로-벤조푸란-7-일)에톡시)-3-(S)-(4-플루오로)페닐-4-(4-(2-옥소-13, -이미다졸로)메틸-모르폴린; 506) 2-(R)-(1)-(R)-(3, 5-(디메톡시)페닐)에톡시)-3-(S)-(4-플루오로)페닐-모르폴린; 507) 2-(R)-(1)-(R)-(3, 5-(디메톡시)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H, 4H-1, 2, 4-트리아졸로)메틸-모르폴린; 508) 2-9R)-(1-(R)-(3,5-(디메톡시)페닐에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(1, 2, 4-트리아졸로)메틸-모르폴린; 509) 2-(R)-(1-(R)-(3,5-(디메톡시)페닐)에톡시-3-(S)-(4-플루오로)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 510) 2-(R)-(1-(R)-(페닐)에톡시)-3-(S)-페닐-모르폴린; 511) 2-(R)-(1-(R)-(페닐)에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H, 4H- 1, 2, 4-트리아졸로)메틸)-모르폴린; 512) 2-(R)-(1-(R)-(페닐)에톡시-3-(S)-페닐-4-(3-(1, 2, 4-트리아졸로)메틸)-모르폴린; 513) 2-(R)-(1-(R)-(페닐)에톡시)-3-(S)-페닐-4-(4-(2-옥소-1, 3-이미다졸로)메틸)-모르폴린; 514) 2-(R)-(1-(R)-(페닐)에톡시)-3-(S)-(4-플루오로)페닐-모르폴린; 515) 2-(R)-(1-(R)-(페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H, 4H, -1, 2, 4-트리아졸로)메틸)-모르폴린; 516) 2-(R)-(1-(R)-(페닐)에톡시)-3-(S)-(4-플루오로)페닐)-4-(3-(1, 2, 4-트리아졸로)메틸)-모르폴린; 517) 2-(R)-(1-(R)-(페닐)에톡시)-3-(S)-(4-플루오로)페닐)-4-(4-(2-옥소-1, 3-이미다졸로)메틸)-모르폴린; 518) 2-(R)-(1-(R)-(3-(플루오로)페닐)에톡시)-3-(S)-페닐-모르폴린; 519) 2-(R)-(1-(R)-(3-(플루오로)페닐)에톡시)-3-(S)-페닐-4-(3-(5-옥소-1H, 4H-1, 2, 4-트리아졸로)메틸)-모르폴린; 520) 2-(R)-(1-(R)-(3-(플루오로)페닐)에톡시)-3-(S)-페닐-4-(3-(1, 2, 4-트리아졸로)메틸)-모르폴린; 521) 2-(R)-(1-(R)-(3-(플루오로)페닐)에톡시)-3-(S)-
    페닐-4-(4-(2-옥소-1, 3-이미다졸로)메틸)-모르폴린; 522) 2-(R)-(1-(R)-(3-(플루오로)페닐)에톡시)-3-(S)-(4-플루오로)페닐-모르폴린; 523) 2-(R)-(1-(R)-(3-(플루오로)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H, 4H-1, 2, 4-트리아졸로)메틸)-모르폴린; 524) 2-(R)-(1-(R)-(3-(플루오로)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(1, 2, 4-트리아졸로)메틸)-모르폴린; 525) 2-(R)-(1-(R)-(3-(플루오로)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 526) 2-(R)-(1-(R)-(3-(플루오로)페닐)에톡시)-3-(S)-(4-플루오로)페닐-모르폴린; 527) 2-(R)-(1-(R)-(3-(플루오로)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H, 4H,-1, 2, 4-트리아졸로)메틸)-모르폴린; 528) 2-(R)-(1-(R)-(3-(플루오로)페닐)에톡시)-3-(S)-페닐-4-(3-(1, 2, 4-트리아졸로)메틸)-모르폴린; 529) 2-(R)-(1-(R)-(3-(플루오로)페닐)에톡시)-3-(S)-페닐-4-(4-(2-옥소-1,3-이디미다졸로)메틸)-모르폴린; 530) 2-(R)-(1-(R)-(3-(플루오로)페닐)에톡시)-3-(S)-(4-플루오로)페닐-모르폴린; 531) 2-(R)-(1-(R)-(3-(플루오로)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(5-옥소-1H, 4H, -1, 2, 4-트리아졸로)메틸)-모르폴린; 532) 2-(R)-(1-(R)-(4-(플루오로)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(3-(1, 2, 4-트리아졸로)메틸)-모르폴린 ; 533) 2-(R)-(1-(R)-(4-(플루오로)페닐)에톡시)-3-(S)-(4-플루오로)페닐-4-(4-(2-옥소-1, 3-이미다졸로)메틸)-모르폴린; 534) 2-(R)-(1-(R)-(3, 5-(비스(트리플루오로메틸)페닐)에톡시-3-(S)-(3-플루오로)페닐-모르폴린; 535) 2-(R)-(1-(R)-(3, 5-(비스(트리플루오로메틸)페닐)에톡시-3-(S)-(3-플루오로)페닐-4-(3-(5-옥소-1H, 4H-1, 2, 4-트리아졸로)메틸)-모르폴린; 536) 2-(R)-(1-(R)-(3, 5-(비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(3-플루오로)페닐-4-(3-(1,2,4-트리아졸로)메틸)-모르폴린; 537) 2-(R)-(1-(R)-(3, 5-(비스(트리플루오로메틸)페닐)에톡시-3-(S)-(3-플루오로)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 538) 2-(R)-(1-(R)-(3, 5-(비스(트리플루오로메틸)페닐)에톡시-3-(S)-(3, 4-디플루오로)페닐-모르폴린; 539) 2-(R)-(1-(R)-(3, 5-(비스(트리플루오로메틸)페닐)에톡시-3-(S)-(3, 4-디플루오로)페닐-4-(3-(5-옥소-1H, 4H-1, 2, 4-트리아졸로)메틸)-모르폴린; 540) 2-(R)-(1-(R)-(3, 5-(비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(3, 4-디플루오로)페닐-4-(3-(1, 2, 4-트리아졸로)메틸)-모르폴린; 541) 2-(R)-(1-(R)-(3, 5-(비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(3, 4-디플루오로)페닐-4-(4-(2-옥소-1, 3-이미다졸로)메틸)-모르폴린; 542) 2-(R)-(1-(R)-(3, 5-(비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(3, 4-디클로로)페닐-모르폴린; 543) 2-(R)-(1-(R)-(3, 5-(비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(3, 4-디클로로)페닐-4-(3-(5-옥소-1H, 4H-1, 2, 4-트리아졸로)메틸)-모르폴린; 544) 2-(R)-(1-(R)-(3, 5-(비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(3, 4-디클로로)페닐-4-(3-(1, 2, 4-트리아졸로)메틸)-모르폴린; 545) 2-(R)-(1-(R)-(3, 5-(비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(3, 4-디클로로)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 546) 2-(R)-(1-(R)-(3, 5-(비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(3, 4-디메틸)페닐-모르폴린; 547) 2-(R)-(1-(R)-(3, 5-(비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(3, 4-디메틸)페닐-4-(3-(5-옥소-1H, 4H-1, 2, 4-트리아졸로)메틸)-모르폴린; 548) 2-(R)-(1-(R)-(3, 5-(비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(3, 4-디메틸)페닐-4-(3-(1, 2, 4-트리아졸로)메틸)-모르폴린; 549) 2-(R)-(1-(R)-(3, 5-(비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(3, 4-디메틸)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 550) 2-(R)-(1-(R)-(3, 5-(비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(3, 4-메틸렌디옥시페닐)-모르폴린; 551) 2-(R)-(1-(R)-(3, 5-(비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(3, 4-메틸렌디옥시페닐-4-93-(5-옥소-1H, 4H-1,2,4-트리아졸로)메틸)-모르폴린; 552) 2-(R)-(1-(R)-(3, 5-(비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(3, 4-메틸렌디옥시페닐-4-(3-(1, 2, 4-트리아졸로)메틸)-모르폴린; 553) 2-(R)-(1-(R)-(3, 5-(비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(3, 4-메틸렌디옥시페닐-4-(4-옥소-1,3-이미다졸로)메틸)-모르폴린; 554) 2-(R)-(1-(R)-(3, 5-(비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(2-나프틸)-모르폴린; 555) 2-(R)-(1-(R)-(3, 5-(비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(2-나프틸)-43(3-5-옥소-1H, 4H-1, 2, 4-트리아졸로)메틸)-모르폴린; 556) 2-(R)-(1-(R)-(3, 5-(비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(2-나프틸)-4-(3-1, 2, 4-트리아졸로)메틸)-모르폴린; 557) 2-(R)-(1-(R)-(3, 5-(비스(트리플루오로메틸)페닐)에톡시)-3-(S)-(2-나프틸)-4-(4-2-옥소-1, 3-이미다졸로)메틸)-모르폴린; 558)2-(R)-(1-(R)-(3-플로오로페닐)-5-(트리플루오로메틸)에톡시)-3-(S)-페닐-4-(3-(1, 2, 4-트리아졸로)메틸)-모르폴린; 559) 2-(R)-(1-(R)-(3-플로오로페닐)-5-(트리플루오로메틸)에톡시)-3-(S)-페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴리; 560) 2-(R)-(1-(R)-(3-클로로페닐)-5-(트리플루오로메틸)에톡시)-3-(S)-페닐-4-(3-(1, 2, 4-트리아졸로)메틸)-모르폴린; 561) 2-(R)-(1-(R)-(3-클로로페닐)-5-(트리플루오로메틸)에톡시)-3-(S)-페닐-4-(4-92-옥소-1, 3-이미다졸로)메틸)-모르폴린; 562) 2-(R)-(1-(R)-(3-클로로페닐)-5-(트리플루오로메틸)에톡시)-3-(S)-페닐-4-(3-(1, 2, 4-트리아졸로)메틸-모르폴린; 563) 2-(R)-(1-(R)-(3, 5-(디메틸)페닐)에톡시-3-(S)-페닐-4-(4-(2-옥소-1, 3-이미다졸로)메틸)-모르폴린; 564) 2-(R)-(1-(R)-(3-(플루오로)-5-(메틸)페닐)에톡시)-3-(S)-페닐)-4-(3-(1, 2, 4-트리아졸로)메틸)-모프폴린; 565) 2-(R)-(1-(R)-(3-(플루오로)-5-(메틸)페닐)에톡시)-3-(S)-페닐-4-(4-2(옥소-1, 3-이미다졸로)메틸)-모르폴린; 566) 2-(R)-(1-(R)-(3-(클로로)-5-(메틸)페닐)에톡시)-3-(S)-페닐-4-(3-(-1H, 4H-1, 2, 4-트리아졸로)메틸)-모르폴린; 567) 2-(R)-(1-(R)-(3-(클로로)-5-(메틸)페닐)에톡시)-3-(S)-페닐-4-(4-(2-옥소-1, 3-이미다졸로)메틸-모르포린; 568) 2-(R)-(1-(R)-(3-(브로모)-5-(메틸)페닐)에톡시)-3-(S)-페닐-4-(3-1, 2, 4-트리아졸로)메틸)-모르폴린; 569) 2-(R)-(1-(R)-(3-(브로모)-5-(메틸)페닐)에톡시)-3-(S)-페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 570) 2-(R)-(1-(R)-(3-(이소프로폭시)페닐)에톡시)-3-(S)-페닐-4-(3-(1, 2, 4-트리아졸로)메틸-모르폴린; 571) 2-(R)-(1-(R)-(3-(이소프로폭시)페닐)에톡시)-3-(S)-페닐-4-(4-(2-옥소-, 3-이마다졸로)메틸)-모르폴린; 572) 2-(R)-(1-(R)-(3-(이소프로폭시)-5-(트리플루오로메틸)페닐)에톡시)-3-(S)-페닐-4-(3-(-1H, 4H-1, 2, 4-트리아졸로)메틸)-모르폴린; 573) 2-(R)-(1-(R)-(3-(이소프로폭시)-5-(트리플루오로메틸)페닐)에톡시)-3-(S)-페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모프폴린; 574) 2-(R)-(1-(R)-(3-(클로로)-5-(이소프로폭시)페닐)에톡시)-3-(S)-페닐-4-(3-(-1H, 4H, -1, 2, 4-트리아졸로)메틸)-모르폴린; 575) 2-(R)-(1-(R)-(3-(클로로)-5-(이소프로폭시)페닐)에톡시)-3-(S)페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 576) 2-(R)-(1-(R)-(3-(플루오로)-5-(이소프로폭시)페닐)에톡시)-3-(S)-페닐-4-(3-(-1H, 4H-1, 2, 4-트리아졸로)메틸)-모르폴린; 577) 2-(R)-(1-(R)-(3-(플루오로)-5-(이소프로폭시)페닐)에톡시)-3-(S)-페닐-4-(4-2(옥소-1, 3-이미다졸로)메틸)-모르폴린; 578) 2-(R)-(1-(R)-(3-(t-부틸)-5-(클로로)페닐)에톡시)-3-(S)-페닐-4-(3-(-1H, 4H-1, 2, 4-트리아졸로)메틸)-모로폴린; 579) 2-(R)-(1-(R)-(3-(t-부틸)-5-(클로로)페닐)에톡시)-3-(S)-페닐-4-94-(2-옥소-1,3-이미다졸로)메틸-모르폴린; 580) 2-(R)-(1-(R)-(3-(t-부틸)-5-(트리플루오로메틸)페닐)에톡시)-3-(S)-페닐-4-(3-(-1H, 4H-1, 2, 4-트리아졸로)메틸)-모프폴린; 581) 2-(R)-(1-(R)-(3-(t-부틸)-5-(트리플루오로메틸)페닐)에톡시)-3-(S)-페닐-4-(4-(2-옥소-1, 3-이미다졸로)메틸)모르폴린; 582) 2-(R)-(1-(R)-(3, 5(디메틸)-5-(플루오로)페닐)에톡시)-3-(S)-페닐-4-93-(1, 2, 4-트리아졸로)메틸)-모르폴
    린; 583) 2-(R)-(1-(R)-(3, 5(디메틸)-5-(플루오로)페닐)에톡시)-3-(S)-페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 584) 2-(R)-(1-(R)-(3, 5(디메틸)-4-(클로로)페닐)에톡시)-3-(S)-페닐-4-(3-(-1H, 4H-1, 2, 4-트리아졸로)메틸)-모르폴린; 585) 2-(R)-(1-(R)-(3, 5(디메틸)-4-(클로로)페닐)에톡시)-3-(S)-페닐-4-(4-(2-옥소-1, 3-이미다졸로)메틸)-모르폴린; 586) 2-(R)-(1-(R)-(3, 5-비스(트리플루오로메틸)-4-(플루오로)페닐)에톡시)-3-(S)-페닐-4-(3-(-1H, 4H-1, 2, 4-트리아졸로)메틸)-모르폴린; 587) 2-(R)-(1-(R)-(3, 5-비스(트리플루오로메틸)-4-(플루오로)페닐)에톡시)-3-(S)-페닐-4-(4-(2-옥소-1, 3-이미다졸로)메틸)-모르폴린; 588) 2-(R)
    -(1-(R)-(3, 5-비스(트리플루오로메틸)-4-(클로로)페닐)에톡시)-3-(S)-페닐-4-(3-(-1H, 4H-1, 2, 4-트리아졸로)메틸)-모르폴린; 589) 2-(R)-(1-(R)-(3, 5-비스(트리플루오로메틸)-4-(클로로)페닐)에톡시)-3-(S)-페닐-4-(4-(2-옥소-1, 3-이미다졸로)메틸)-모르폴린; 590) 2-(R)-(1-(R)-(3, 5-(디클로로)페닐)에톡시)-3-(S)-페닐-4-(3-(-1H, 4H-1, 2, 4-트리아졸로)메틸)-모르폴린;591) 2-(R)-(1-(R)-(3, 5-(디클로로)페닐)에톡시)-3-(S)-페닐-4-(4-(2-옥소-1, 3-이미다졸로)메틸)-모르폴린; 592) 2-(R)-(1-(R)-(3, 5-(디플루오로)페닐)에톡시)-3-(S)-페닐-4-(3-(1, 2, 4-트리아졸로)메틸)-모르폴린; 593) 2-(R)-(1-(R)-(3, 5-(디플루오로)페닐)에톡시)-3-(S)-페닐-4-(4-(2-옥소-1, 3-이미다졸로)메틸)-모르폴린; 594) 2-(R)-(1-(R)-(1-(나프틸)에톡시)-3-(S)-페닐-4-(3-(1, 2, 4-트리아졸로)메틸-모르폴린; 595) 2-(R)-(1-(R)-(1-(나프틸)에톡시)-3-(S)-페닐-4-(4-(2-옥소-1, 3-이미다졸로)메틸-모르폴린; 596) 2-(R)-(1-(R)-(1-(4-(플루오로)나프틸)에톡시)-3-(S)-페닐-4-(3-(1, 2, 4-트리아졸로)메틸)-모르폴린; 597) 2-(R)-(1-(R)-(1-(4-(플루오로)나프틸))에톡시)-3-(S)-페닐-4-(2-옥소-1, 3-이미다졸로)메틸)-모르폴린;598) 2-(R)-(1-(R)-(1-(3-(플루오로)나프틸))에톡시)-3-(S)-페닐-4-(3-(1, 2, 4-트리아졸로)메틸)-모르폴린; 599) 2-(R)-(1-(R)-(1-(3-(플루오로)나프틸))에톡시)-3-(S)-페닐-4-(4-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 600) 2-(R)-(1-(R)-(1-(3-(클로로)나프틸))에톡시)-3-(S)-페닐-4-(3-(1, 2, 4-트리아졸로)메틸)-모르폴린; 601) 2-(R)-(1-(R)-(1-(3-(클로로)나프틸))에톡시)-3-(S)-페닐-4-94-(2-옥소-1,3-이미다졸로)메틸)-모르폴린; 및 이의 약제학적으로 허용되는 염으로 이루어진 그룹으로부터 선택되는 모 화합물의 프로드러그.
  17. 제16항에 있어서, 포스포릴 그룹을 포함하는 프로드러그.
  18. 약제학적으로 허용되는 담체 및 유효량의 제1항에 따른 화합물을 포함하는 약제학적 조성물.
  19. 제18항에 있어서, 약제학적으로 허용되는 담체가 물을 포함하는 약제학적 조성물.
  20. 제18항에 있어서, 약제학적으로 허용되는 담체가 생리학적으로 허용되는 생리식염수를 포함하는 약제학적 조성물.
  21. 포유동물에 제1항에 따른 화합물을 포유동물의 수용체 부위에서 물질 P의 효과를 길항시키는 데 유효한 양으로 투여함을 포함하는, 포유동물의 뉴로키닌-1 수용체를 차단시키거나 그의 수용체 부위에서 물질 P의 효가를 길항시키는 방법.
  22. 편두통의 원인이 되거나 또는 그와 관련된 동통 또는 유해수용의 치료 또는 예방을 요하는 포유동물에 유효량의 제1항에 따른 화합물을 투여함을 포함하는, 포유동물의 동통 또는 유해수용을 치료 또는 예방하는 방법.
  23. 당뇨 신경병, 말초 신경병, AIDS 관련 신경병, 화학요법-유도 신경병 및 신경통으로 이루어진 그룹으로부터 선택되는 중상의 치료 또는 예방을 요하는 포유동물에 유효량의 제1항에 따른 화합물을 투여함을 포함하는, 포유동물의 상기 증상을 치료 또는 에방하는 방법.
  24. 천식의 치료 또는 예방을 요하는 포유동물에 유효량의 제1항에 따른 화합물을 단독으로 또는 뉴로키닌-2 수용체 길항제 또는 β2-아드레날린 수용체 활성제와 조합하여 투여함을 포함하는, 포유동물의 천식을 치료 또는 예방하는 방법.
  25. 낭포성 섬유중의 치료를 요하는 포유동물에 유효량의 제1항에 따른 화합물을 투여하는 것을 포함하는, 포유동물의 낭포성 섬유증을 치료하는 방법.
  26. 구토의 치료 또는 예방을 요하는 포유동물에 유효량의 제1항에 따른 화합물을 투여함을 포함하는, 포유 동물의 구토를 치료 또는 예방하는 방법.
  27. 관절염의 치료 또는 예방을 요하는 포유동물에 유효량의 제1항에 따른 화합물을 투여함을 포함하는, 포유동물의 관절염을 치료 또는 예방하는 방법.
  28. X가 수소가 아닌 것을 제외하고는 하기 정의한 바와 같은 화학식(1)의 화합물을 적합한 염기의 존재하에 적절한 프로드러그 전이 시약과 다음 화학식(1)의 화합물을 생성하기에 충분한 시간 동안 접촉시키는 것을 포함하는, 다음 화학식(1)의 화합물을 제조 방법.
    상기 식에서, R2및 R3은 (1) 수소, (2) 비치환되거나 (a) 히드록시, (b) 옥소, (c)C1-6알콕시, (d) 페닐-C1-3알콕시, (e) 페닐, (f) -CN, (g) 할로, (h) -NR9R10은〔여기서, R9및 R10은 (i) 수소, (ii) C1-6알킬, (iii) 히드록시-C1-6알킬 및 (iv) 페닐로부터 독립적으로 선택됨.〕 (i) -NR9COR10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (j) -NR9CO2R10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (k) -CONR9R10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (l) -COR9〔여기서, R9는 상기 정의된 바와 같음〕 및, (m) -CO2R9〔여기서, R9는 상기 정의된 바와 같음〕으로부터 선택되는 1개 이상의 치환체로 치환된 C1-6알킬, (3) 비치환되거나 (a) 히드록시, (b) 옥소, (c)C1-6알콕시, (d) 페닐-C1-3알콕시, (e) 페닐, (f) -CN, (g) 할로, (h) -CONR9R10은〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (i) -COR9〔여기서, R9는 상기 정의된 바와 같음〕 및 (j) -CO2N9〔여기서, R9는 상기 정의된 바와 같음〕으로부터 선택되는 1개 이상의 치환체로 치환된 C2-6알케닐, (4) C2-6알키닐 및 (5) 비치환되거나 (a) 히드록시, (b) C1-6알콕시, (c)C1-6알킬, (d) C2-5알케닐, (e) 할로, (f) -CN, (g) -NO2, (h) -CF3, (i) -(CH2)m-NR9R10〔여기서, m, R9및 R10은 상기 정의된 바와 같음〕, (j) -NR9COR10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (k) -NR9CO2R10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (l) -CONR9R10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (m) -CO2NR9R10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (n) -COR9〔여기서, R9는 상기 정의된 바와 같음〕 및 (o) -CO2R9〔여기서, R9는 상기 정의된 바와 같음〕으로부터 선택되는 1개 이상의 치환체로 치환된 페닐로 이루어진 그룹으로부터 독립적으로 선택되고; 또한 R2및 R3은 함께 결합하여 (a) 시클로펜틸, (b) 시클로헥실 및 (c) 페닐로 이루어진 글부으로부터 선택되는 카르보시클릭 환〔여기서, 카르보시클릭 환은 비치환되거나 (i) C1-6알킬, (ii) C1-6알콕시, (iii) -NR9R10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (iv) 할로 및 (v) 트리플루오로메틸로부터 선택되는 1개 이상의 치환체로 치환됨〕을 형성하고; 또한 R2및 R3은 함께 결합하여 (a) 피롤리디닐, (b) 피페리디닐, (c) 피롤릴, (d) 피리디닐, (e) 이미다졸릴, (f) 푸라닐, (g) 옥사졸릴, (h) 티에닐 및 (i) 티아졸릴로 이루어지는 그룹으로부터 선택되는 헤테로시클릭 환〔여기서, 헤테로시클릭 환은 비치환되거나 (i) C1-6알콕시, (ii) 옥소, (iii) C1-6알콕시, (iv) -NR9R10(여기서, R9및 R10은 상기 정의된 바와 같음〕, (v) 할로, 및 (vi) 트리플루오로메틸로부터 선택되는 1개 이상의 치환체로 치환됨〕을 형성하고; R6, R7및 R8은 (1) 수소, (2) 비치환되거나 또는 (a) 히드록시, (b) 옥소, (c) C1-6알콕시, (d) 페닐-C1-3알콕시, (e) 페닐, (f) -CN, (g) 할로, (h) -NR9R10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (i) -NR9COR10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (j) -NR9CO2R10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (k) -CONR9R10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (l) -COR9〔여기서, R9및 R10은 상기 정의된 바와 같음〕, 및 (m) -CO2R9〔여기서, R9상기 정의된 바와 같음〕으로부터 선택되는 1개 이상의 치환체로 치환된 C1-6알킬, (3) 비치환되거나 (a) 히드록시, (b) 옥소, (c) C1-6알콕시, (d) 페닐-C1-3알콕시, (e) 페닐, (f) -CN, (g) 할로, (h) -CONR9R10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (i) -COR9〔여기서, R9는 상기 정의된 바와 같음〕 및 (j) -CO2R9〔여기서, R9는 상기 정의된 바와 같음〕으로부터 선택되는 1개 이상의 치환체로 치환된 C2-6알케닐, (4) C2-6알키닐, (5) 비치환되거나 (a) 히드록시, (b) C1-6알콕시, (c)C1-6알킬, (d) C2-5알케닐, (e) 할로, (f) -CN, (g) -NO2, (h) -CF3, (i) -(CH2)m-NR9R10〔여기서, m, R9및 R10은 상기 정의된 바와 같음〕, (j) -NR9COR10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (k) -NR9CO2R10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (l) -CONR9R10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (m) -CO2NR9R10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (n) -COR9〔여기서, R9는 상기 정의된 바와 같음〕 및 (o) -CO2R9〔여기서, R9는 상기 정의된 바와 같음〕으로부터 선택되는 1개 이상의 치환체로 치환된 페닐, (6) 할로, (7) -CN, (8) -CF3, (9) -NO2, (10) -SR14(여기서, R14는 수소 또는 C1-5알킬임), (11) -SOR14(여기서, R14는 상기 정의된 바와 같음), (12) -SO2R14(여기서, R14는 상기 저의된 바와 같음), (13) NR9COR10(여기서, R9및 R10은 상기 정의된 바와 같음), (14) CONR9COR10(여기서, R9및 R10은 상기 정의된 바와 같음), (15) NR9R10(여기서, R9및 R10은 상기 정의된 바와 같음), (16) NR9CO2R10(여기서, R9및 R10은 상기 정의된 바와 같음), (17) 히드록시, (18) C1-6알콕시, (19) COR9(여기서, R9는 상기 정의된 바와 같음), (20) CO2R9(여기서, R9는 상기 정의된 바와 같음) , (21) 2-피리딜, (22) 3-피리딜, (23) 4-피리딜, (24) 5-테트라졸릴, (25) 2-옥사졸릴 및 (26) 2-티아졸릴로 이루어진 그룹으로부터 독립적으로 선택되고; R11, R12및 R13은 R6, R7및 R8의 정의들 또는 -OX로부터 독립적으로 선택되고; A는 (1) 비치환되거나 (a) 히드록시, (b) 옥소, (c) C1-6알콕시, (d) 페닐-C1-3알콕시, (e)페닐, (f) -CN (g) 할로〔여기서, 할로는 플루오로, 클로로, 브로모 또는 요오도임〕, (h) -NR9R10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (i) -NR9COR10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (j) -NR9CO2R10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (k) -CONR9R10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (l) -COR9〔여기서, R9는 상기 정의된 바와 같음〕 및 (m) -CO2R9〔여기서, R9는 상기 정의된 바와 같음〕으로부터 선택되는 1개 이상의 치환체로 치환된 C1-6알킬, (2) 비치환되거나 또는 (a) 히드록시, (b) 옥소, (c) C1-6알콕시, (d) 페닐-C1-3알콕시, (e)페닐, (f) -CN (g) 할로, (h) -CONR9R10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (i) -COR9〔여기서, R9는 상기 정의된 바와 같음〕 및 (j) -CO2R9〔여기서, R9는 상기 정의된 바와 같음〕으로부터 선택되는 1개 이상의 치환체로 치환된 C2-6알케닐 및 (3) C2-6알키닐로 이루어진 그룹으로부터 선택되고; B는 헤테로사이클〔여기서, 헤테로사이클은
    으로 이루어진 그룹으로부터 독립적으로 선택되고, -X에 더하여 (i) 수소, (ii) 비치환되거나 또는 할로, -CF3, -OCH3또는 페닐로 치환된 C1-6알킬, (iii) C1-6알콕시, (iv) 옥소, (v) 히드록시, (vi) 티옥소, (vii) -SR9〔여기서, R9는 상기 정의된 바와 같음〕, (viii) 할로, (ix)시아노, (x) 페닐, (xi) 트리플루오로메틸, (xii) -(CH2)m-NR9R10〔여기서, m은 0, 1 또는 2이고, R9, R10은 상기 정의된 바와 감음〕, (xiii) -NR9COR10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (xiv) -CONR9R10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (xv) -CO2R9〔여기서, R9는 상기 정의된 바와 같음〕 및 (xvi) -(CH2)m-OR9〔여기서, m 및 R9는 상기 정의된 바와 같음〕으로부터 선택되는 1개 이상의 치환체로 치환됨〕이고; p는 0 또는 1이고; X는 (a) -PO(OH)O·M(여기서, M는 약제학적으로 허용되는 1가 역이온임), (b) -PO(O)2·2M, (c) -PO(O)2·D2 (여기서, D2 는 약제학적으로 허용되는 2가 역이온임), (d) -CH(R4)-PO(OH)O·M(여기서, R4는 수소 또는 C1-3알킬임), (e) CH(R4)-PO(O)2·2M, (f) -CH(R4)-PO(O)2·D2 , (g) -SO3 ·M, (h) -CH(R4)-SO3 ·M, (i) -CO-CH2CH2-CO2 ·M, (j) -CH(CH3)-O-CO-R5〔여기서, R5는
    으로 이루어진 그룹으로부터 선택됨〕 및 (k) 수소〔단, p가 0이고, R11, R12또는 R13중 어느 것도 -OX가 아닌 경우에는 X는 수소가 아님〕로부터 선택되고; Y는 (1) 단일 결합, (2) -O-, (3) -S-, (4) -CO-, (5) -CH2- (6) -CHR15-, 및 (7) -CR15R16-〔여기서, R15및 R16은 (a) 비치환되거나 또는 (i) 히드록시, (ii) 옥소, (iii) C1-6알콕시, (iv) 페닐-C1-3알콕시, (v) 페닐, (vi) -CN, (vii) 할로, (viii) -NR9R10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (ix) -NR9COR10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (x) -NR9CO2R10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (xi) -CONR9R10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (xii) -COR9〔여기서, R9는 상기 정의된 바와 같음〕, (xiii) -CO2R9〔여기서, R9는 상기 정의된 바와 같음〕으로부터 선택되는 1개 이상의 치환체로 치환된 C1-6알킬 및 (b) 비치환되거나 또는 (i) 히드록시, (ii) C1-6알콕시, (iii) C1-6알킬, (iv) C2-5알케닐, (v) 할로, (vi) -CN, (vii) -NO2, (viii) -CF3, (ix) -(CH2)m-NR9R10〔여기서, m, R9및 R10은 상기 정의된 바와 같음〕, (x) -NR9COR10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (xi) -NR9CO2R10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (xii) -CONR9R10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (xiii) -CO2NR9R10〔여기서, R9및 R10은 상기 정의된 바와 같음〕, (xiv) -COR9〔여기서, R9는 상기 정의된 바와 같음〕및 (xv) -CO2R9〔여기서, R9는 상기 정의된 바와 같음〕으로부터 선택되는 1개 이상의 치환체로 치환된 페닐로 이루어진 그룹으로부터 독립적으로 선택됨〕로 이루어진 그룹으로부터 선택되고; Z는 (1) 수소, (2) C1-6알킬, 및 (3) 히드록시〔단, Y가 -O-인 경우, Z는 히드록시가 아니거나, 또는 Y가 -CHR15-인 경우에는 Z 및 R15는 임의로 함께 결합하여 이중 결합을 형성함〕으로부터 선택된다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960704865A 1994-03-04 1995-02-28 모르폴린 태키키닌 수용체 길항제의 프로드러그(Prodrugs of morpholine tachykinin receptor antagonists) KR977001713A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20677194A 1994-03-04 1994-03-04
US8/206,771 1994-03-04
PCT/US1995/002551 WO1995023798A1 (en) 1994-03-04 1995-02-28 Prodrugs of morpholine tachykinin receptor antagonists

Publications (1)

Publication Number Publication Date
KR977001713A true KR977001713A (ko) 1997-04-12

Family

ID=22767887

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960704865A KR977001713A (ko) 1994-03-04 1995-02-28 모르폴린 태키키닌 수용체 길항제의 프로드러그(Prodrugs of morpholine tachykinin receptor antagonists)

Country Status (30)

Country Link
US (4) US5512570A (ko)
EP (1) EP0748320B1 (ko)
JP (1) JP3073770B2 (ko)
KR (1) KR977001713A (ko)
CN (1) CN1075812C (ko)
AT (1) ATE227722T1 (ko)
AU (1) AU700611B2 (ko)
BG (1) BG62811B1 (ko)
BR (1) BR9507046A (ko)
CA (1) CA2183250C (ko)
CO (1) CO4340689A1 (ko)
CZ (1) CZ288241B6 (ko)
DE (2) DE69528823T2 (ko)
ES (1) ES2184794T3 (ko)
FI (1) FI963450A0 (ko)
FR (1) FR08C0019I2 (ko)
HR (1) HRP950099A2 (ko)
HU (1) HUT76324A (ko)
IL (1) IL112778A0 (ko)
LV (1) LV11688B (ko)
MX (1) MX9603845A (ko)
NO (1) NO310074B1 (ko)
NZ (1) NZ282586A (ko)
PL (1) PL180522B1 (ko)
RU (1) RU2170233C2 (ko)
SK (1) SK112396A3 (ko)
TW (1) TW385308B (ko)
WO (1) WO1995023798A1 (ko)
YU (1) YU14495A (ko)
ZA (1) ZA951780B (ko)

Families Citing this family (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
ATE278687T1 (de) * 1993-12-29 2004-10-15 Merck Sharp & Dohme Substituierte morpholinderivate und ihre verwendung als therapeutische mittel
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5747491A (en) * 1994-05-05 1998-05-05 Merck Sharp & Dohme Ltd. Morpholine derivatives and their use as antagonists of tachikinins
GB9505491D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9523244D0 (en) * 1995-11-14 1996-01-17 Merck Sharp & Dohme Therapeutic agents
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
US5750549A (en) * 1996-10-15 1998-05-12 Merck & Co., Inc. Cycloalkyl tachykinin receptor antagonists
US6100256A (en) * 1996-12-02 2000-08-08 Merck Sharp & Dohme Ltd. Use of NK-1 receptors antagonists for treating schizophrenic disorders
US6613765B1 (en) * 1996-12-02 2003-09-02 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating major depressive disorders
JP2001504852A (ja) * 1996-12-02 2001-04-10 メルク シヤープ エンド ドーム リミテツド 双極性障害の治療のためのｎｋ−１受容体拮抗薬の使用
US6114315A (en) * 1996-12-02 2000-09-05 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
CA2273853A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating cognitive disorders
US5977104A (en) * 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
EP0942732B1 (en) * 1996-12-02 2004-11-17 MERCK SHARP & DOHME LTD. Use of nk-1 receptor antagonists for treating movement disorders
EP0942728A1 (en) * 1996-12-02 1999-09-22 MERCK SHARP & DOHME LTD. Use of nk-1 receptor antagonists for treating sexual dysfunction
CA2287487A1 (en) * 1997-04-24 1998-10-29 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating eating disorders
CA2298779A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
GB9716457D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
CA2298777A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating mania
US6087348A (en) * 1997-12-01 2000-07-11 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating stress disorders
GB9813025D0 (en) * 1998-06-16 1998-08-12 Merck Sharp & Dohme Chemical synthesis
GB9816897D0 (en) * 1998-08-04 1998-09-30 Merck Sharp & Dohme Therapeutic use
EP1035115B1 (en) 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
YU59901A (sh) 1999-02-24 2005-07-19 F. Hoffmann-La Roche Ag. Derivati 3-fenilpiridina i njihova primena kao antagonista nk-1 receptora
KR100514236B1 (ko) 1999-02-24 2005-09-13 에프. 호프만-라 로슈 아게 페닐 유도체 및 피리디닐 유도체
US6291465B1 (en) 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
FR2792835B3 (fr) * 1999-04-27 2001-05-25 Sanofi Sa Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
US6552025B1 (en) * 1999-11-24 2003-04-22 Emory University Diimino-piperazine derivatives for use as modulators of cell regulation
DE60006340T2 (de) * 1999-11-29 2004-09-09 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramid
US6452001B2 (en) 2000-05-25 2002-09-17 Hoffmann-La Roche Inc. Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
SI1303490T1 (sl) 2000-07-14 2008-10-31 Hoffmann La Roche N-oksidi kot predzdravila NK 1 receptorskega antagonista 4-fenil-piridin derivatov
TWI287003B (en) 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
YU39503A (sh) 2000-11-22 2006-05-25 F. Hoffmann-La Roche Ag. Derivati pirimidina
US6642226B2 (en) 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
GB0108594D0 (en) * 2001-04-05 2001-05-23 Glaxo Group Ltd Chemical compounds
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US6849624B2 (en) 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
MY130373A (en) * 2001-10-29 2007-06-29 Malesci Sas Linear basic compounds having nk-2 antagonist activity and formulations thereof
US6903129B2 (en) * 2001-12-14 2005-06-07 Hoffman-La Roche Inc. D-proline prodrugs
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
JP2005522436A (ja) * 2002-02-08 2005-07-28 グラクソ　グループ　リミテッド ピペリジルカルボキシアミド誘導体またはそのタキキニン介在疾患の治療における使用
AR039625A1 (es) * 2002-04-18 2005-03-02 Merck & Co Inc Proceso para la preparacion de 5-((2(r)--(1(r)- (3,5-bis (trifluormetil) fenil)etoxi-3 (s) - (4-fluorfenil) -4-morfolinil) metil) -1,2-dihidro-3h-1,2,4-triazol-3-ona
US20060205724A1 (en) * 2002-05-29 2006-09-14 The Regents Of The University Of California Antagonizing nk-1 receptors inhibits consumption of substances of abuse
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
RU2330022C2 (ru) 2003-01-31 2008-07-27 Ф.Хоффманн-Ля Рош Аг НОВАЯ КРИСТАЛЛИЧЕСКАЯ МОДИФИКАЦИЯ 2-(3, 5-БИС-ТРИФТОРМЕТИЛФЕНИЛ)-N-[6-(1, 1-ДИОКСО-1 λ6-ТИОМОРФОЛИН-4-ИЛ)-4-(4-ФТОР-2-МЕТИЛФЕНИЛ)ПИРИДИН-3-ИЛ]-N-МЕТИЛИЗОБУТИРАМИДА
WO2005002577A1 (en) 2003-07-03 2005-01-13 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US7288658B2 (en) 2003-07-15 2007-10-30 Hoffmann-La Roche Inc. Process for preparation of pyridine derivatives
WO2005033079A1 (ja) * 2003-09-30 2005-04-14 Eisai Co., Ltd. ヘテロ環化合物を含有する新規な抗真菌剤
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
NZ548225A (en) 2003-12-31 2012-12-21 Cydex Pharmaceuticals Inc Inhalant formulation containing sulfoakyl ether cyclodextrin and corticosteroid
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
ES2246687B2 (es) 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
ATE446581T1 (de) * 2004-03-12 2009-11-15 Trinity College Dublin Magnetoresistives medium
AU2005237523A1 (en) 2004-04-23 2005-11-10 Cydex Pharmaceuticals, Inc. DPI formulation containing sulfoalkyl ether cyclodextrin
CA2573271C (en) 2004-07-15 2015-10-06 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US20090227799A1 (en) * 2004-08-09 2009-09-10 Kazutaka Nakamoto Novel Antimalarial Agent Containing Heterocyclic Compound
MX2007001713A (es) * 2004-08-11 2007-07-13 Donald L Barbeau Compuestos farmaceuticos no cardiotoxicos.
US7223737B1 (en) 2004-08-13 2007-05-29 Alcon, Inc. Method of treating dry eye disorders using glycosides
AR051475A1 (es) * 2004-11-05 2007-01-17 Merck & Co Inc Procedimiento para acido{3- [2 (r) -[(1r) - 1-[ 3,5- bis( trifluorometil)- fenil] etoxi] -3 (s) - (4- fluorfenil) morfolin -4- il]metil -5-oxo-4,5-dihidro- [1,2,4]-triazol-1-il} fosfonico
ES2329827T3 (es) 2005-02-22 2009-12-01 F. Hoffmann-La Roche Ag Antagonistas de nk1.
AU2006226665B2 (en) 2005-03-23 2011-01-27 Helsinn Healthcare S.A. Metabolites for NK-I antagonists for emesis
US7829585B2 (en) * 2005-03-30 2010-11-09 Eisai R&D Management Co., Ltd. Antifungal agent containing pyridine derivative
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
BRPI0613403A2 (pt) 2005-07-15 2009-02-10 Amr Technology Inc tetrahidrobenzodiazepinas aril- e heteroarila-substituÍdas e uso das mesmas para bloquear a recaptaÇço de norepinefrina, dopamina e serotonina
PT1928427E (pt) 2005-09-23 2010-03-01 Hoffmann La Roche Nova forma galénica
JP4879988B2 (ja) 2005-09-29 2012-02-22 メルク・シャープ・エンド・ドーム・コーポレイション メラノコルチン−４受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
WO2007039883A2 (en) * 2005-10-05 2007-04-12 Ranbaxy Laboratories Limited Process for preparation of aprepitant
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
CA2640966A1 (en) * 2006-02-03 2007-08-09 Glenmark Pharmaceuticals Limited Amorphous and crystalline forms of aprepitant and processes for the preparation thereof
WO2007095341A2 (en) * 2006-02-15 2007-08-23 Tika Läkemedel Ab Sterilization of corticosteroids with reduced mass loss
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008035726A1 (fr) * 2006-09-21 2008-03-27 Eisai R & D Management Co., Ltd. Dérivé de pyridine substitué par un cycle hétéroaryle, et agent antifongique le comprenant
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2336120B1 (en) 2007-01-10 2014-07-16 MSD Italia S.r.l. Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
BRPI0807972A2 (pt) 2007-01-24 2014-06-10 Glaxo Group Ltd Composições farmacêuticas compreendendo 3,5-diamino-6-(2,3-diclofenil)-l,2,4-triazina ou r(-)-2,4-diamino-5-(2,3-diclorofenil)-6-fluorometilpirim idina e uma nk1
EP2145884B1 (en) 2007-04-02 2014-08-06 Msd K.K. Indoledione derivative
CN101657418B (zh) 2007-04-20 2012-05-30 弗·哈夫曼-拉罗切有限公司 作为nk1/nk3受体双重拮抗剂的吡咯烷衍生物
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
CN101622251B (zh) * 2007-04-27 2012-07-04 卫材R&D管理有限公司 杂环取代吡啶衍生物的盐或其结晶
EP1994930A1 (en) * 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CN101778837A (zh) 2007-08-07 2010-07-14 弗·哈夫曼-拉罗切有限公司 作为nk3受体拮抗剂的吡咯烷芳基-醚
US20090076008A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched fosaprepitant
US20090076007A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched aprepitant
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
EP2254420A4 (en) 2008-02-20 2012-02-15 Targia Pharmaceuticals CNS PHARMACEUTICALS AND METHOD FOR THEIR USE
US8598184B2 (en) 2008-03-03 2013-12-03 Tiger Pharmatech Protein kinase inhibitors
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
CA2730681C (en) 2008-07-17 2017-03-07 Glenmark Generics Limited Fosaprepitant dimeglumine intermediate, neutral fosaprepitant, and amorphous fosaprepitant dimeglumine and processes for their preparations
US8188119B2 (en) * 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
EP2393827B1 (en) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
SG174389A1 (en) 2009-03-17 2011-10-28 Daiichi Sankyo Co Ltd Amide derivative
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
ES2662072T3 (es) 2009-05-12 2018-04-05 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y uso de la misma
EP2429295B1 (en) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
UY32799A (es) 2009-07-24 2011-02-28 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
US8188079B2 (en) * 2009-08-19 2012-05-29 Hoffman-La Roche Inc. 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines
KR101485645B1 (ko) 2009-10-14 2015-01-22 머크 샤프 앤드 돔 코포레이션 ｐ53 활성을 증가시키는 치환된 피페리딘 및 그의 용도
WO2011045817A2 (en) * 2009-10-15 2011-04-21 Sandoz Private Limited Process for the preparation of fosaprepitant, intermediate and pharmaceutical acceptable salt thereof
WO2011120044A1 (en) * 2010-03-26 2011-09-29 Duke University Conjugated neuroactive steroid compositions and methods of use
US8487102B2 (en) 2010-04-20 2013-07-16 Hoffmann-La Roche Inc. Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
US20120302558A1 (en) * 2010-07-13 2012-11-29 Sangamesh Badiger Oxazine derivatives and their use in the treatment of neurological disorders
US9446029B2 (en) 2010-07-27 2016-09-20 Colorado State University Research Foundation Use of NK-1 receptor antagonists in management of visceral pain
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
ES2376564B1 (es) 2010-08-12 2013-01-24 Manuel Vicente Salinas Martín Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer.
EP4079856A1 (en) 2010-08-17 2022-10-26 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US8524897B2 (en) 2011-01-12 2013-09-03 Novartis Ag Crystalline oxazine derivative
MY162413A (en) 2011-01-13 2017-06-15 Novartis Ag Novel heterocyclic derivatives and their use in the treatment of neurological disorders
CN102127031B (zh) * 2011-01-17 2012-10-17 江苏江神药物化学有限公司 一种麻黄碱类化合物季胺盐及其合成方法和应用
US9067924B2 (en) * 2011-03-04 2015-06-30 Hoffmann-La Roche Inc. 1,4 thiazepines/sulfones as BACE1 and/or BACE2 inhibitors
FR2973031B1 (fr) * 2011-03-23 2013-11-29 Univ Strasbourg Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
EP2688901B1 (en) * 2011-03-25 2019-05-08 Université Laval INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10
US20140045847A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2012146692A1 (en) 2011-04-29 2012-11-01 Sandoz Ag Novel intermediates for the preparation of highly pure aprepitant or fosaprepitant
KR20140041590A (ko) * 2011-06-07 2014-04-04 에프. 호프만-라 로슈 아게 [1,3]옥사진
WO2013004766A1 (en) 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
CN102977142B (zh) * 2011-09-02 2017-03-29 江苏豪森药业集团有限公司 福沙匹坦二甲葡胺的制备方法
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US20150297613A1 (en) 2011-12-13 2015-10-22 Servicio Andaluz De Salud Use of agents that alter the peritumoral environment for the treatment of cancer
US8338413B1 (en) 2012-03-07 2012-12-25 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders
WO2013168176A2 (en) * 2012-03-30 2013-11-14 Glenmark Generics Limited Process for preparation of fosaprepitant and salt thereof
CZ304982B6 (cs) * 2012-04-30 2015-03-11 Zentiva, K.S. Způsob přípravy a čištění nových polymorfů intermediátu fosaprepitantu
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
CN102675369B (zh) * 2012-05-16 2017-07-11 北京华众思康医药技术有限公司 一种制备[3‑[(2r)‑[(1r)‑1‑[3，5‑二(三氟甲基)苯基]乙氧基]‑3(s)‑(4‑氟苯基)吗啉‑4‑基]甲基]‑5‑氧代‑4，5‑二氢‑[1，2，4]‑三唑‑1‑基]膦酸一苄酯的新方法
ES2701400T3 (es) * 2012-05-31 2019-02-22 Repros Therapeutics Inc Formulaciones para la administración vaginal de antiprogestinas
RS60599B1 (sr) 2012-07-06 2020-08-31 Pharmathen Sa Stabilna injektibilna farmaceutska kompozicija antagonista neurokinin-1-receptora i postupak za njeno dobijanje
EP2900241B1 (en) 2012-09-28 2018-08-08 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US20150119367A1 (en) * 2012-10-29 2015-04-30 Allergan, Inc. Phosphate Esters of Bimatoprost and the Prostamides
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US9126998B2 (en) 2012-11-05 2015-09-08 Bayer Pharma AG Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
US8778964B2 (en) 2012-11-05 2014-07-15 Bayer Pharma Aktiengesellschaft Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use
US8796305B2 (en) 2012-11-05 2014-08-05 Bayer Pharma Aktiengesellschaft Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
SI2925888T1 (en) 2012-11-28 2018-02-28 Merck Sharp & Dohme Corp. Compounds and methods for the treatment of cancer
RU2690663C2 (ru) 2012-12-20 2019-06-05 Мерк Шарп И Доум Корп. Замещенные имидазопиридины в качестве ингибиторов hdm2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
ES2493693B1 (es) 2013-02-11 2015-07-07 Servicio Andaluz De Salud Método para predecir o pronosticar la respuesta de un sujeto humano que padece un cáncer al tratamiento con un antagonista del receptor NK1
WO2014134413A2 (en) * 2013-03-01 2014-09-04 Revlon Consumer Products Corporation Cyrrhetinic alkyl esters and protected derivatives thereof
EP3932932A1 (en) 2013-03-13 2022-01-05 Sage Therapeutics, Inc. Neuroactive steriods and methods of use thereof
US9884067B2 (en) 2013-03-14 2018-02-06 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
EP2987799B1 (en) * 2013-04-18 2020-04-08 Xi'an Libang Pharmaceutical Technology Co.,ltd. Ester derivative of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17beta-diol having antitumour activity and preparation method thereof
CA2914100A1 (en) 2013-06-04 2014-12-11 Bayer Pharma Aktiengesellschaft 3-aryl-substituted imidazo[1,2-a]pyridines and the use thereof
US9808472B2 (en) 2013-08-12 2017-11-07 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015065919A1 (en) 2013-10-28 2015-05-07 The Regents Of The University Of California Treatment of metastatic prostate cancer
CN104650142B (zh) * 2013-11-25 2018-06-22 山东新时代药业有限公司 一种福沙匹坦二甲葡胺的制备方法
CN103694146B (zh) * 2013-12-04 2015-10-28 深圳万乐药业有限公司 2-(2-氯-1-亚乙基)酰肼甲酸甲酯的制备方法
ES2541870B1 (es) 2013-12-27 2016-05-12 Servicio Andaluz De Salud Uso de antagonistas no peptídicos de NK1 en una determinada dosis para el tratamiento del cáncer
JP2017502973A (ja) * 2013-12-30 2017-01-26 オンコプレフェント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌を予防する方法において使用するためのニューロキニン−１受容体アンタゴニスト
CN106459090A (zh) 2014-02-19 2017-02-22 拜耳制药股份公司 3‑(嘧啶‑2‑基)咪唑并[1,2‑a]吡啶
EP3119777A1 (de) 2014-03-21 2017-01-25 Bayer Pharma Aktiengesellschaft Cyano-substituierte imidazo[1,2-a]pyridincarboxamide und ihre verwendung
TW201613888A (en) 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
CN107001361A (zh) 2014-12-02 2017-08-01 拜耳医药股份有限公司 杂芳基取代的咪唑并[1，2‑a]吡啶及其用途
MY197698A (en) 2015-07-06 2023-07-06 Sage Therapeutics Inc Oxysterols and methods of use thereof
US10610532B2 (en) 2015-08-03 2020-04-07 Leiutis Pharmaceuticals Pvt. Ltd. Liquid formulations of fosaprepitant
US10005803B2 (en) 2015-10-06 2018-06-26 Helsinn Healthcare Sa Crystalline forms of fosnetupitant
US9913853B2 (en) 2015-11-03 2018-03-13 Cipla Limited Stabilized liquid fosaprepitant formulations
EP3383829B1 (en) 2015-12-01 2020-10-21 Piramal Enterprises Limited A process for preparation of fosaprepitant dimeglumine and an intermediate thereof
CN105837526B (zh) * 2016-01-22 2018-02-27 浙江工业大学 一种阿瑞吡坦重要合成中间体(2s,3r)‑4‑苄基‑3‑(4‑氟苯基)吗啉‑2‑醇的制备方法
LT3436022T (lt) 2016-04-01 2022-06-27 Sage Therapeutics, Inc. Oksisteroliai ir jų panaudojimo būdai
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN107353303B (zh) 2016-05-09 2020-09-01 上海奥博生物医药技术有限公司 一种福沙匹坦磷酸酯中间体的制备方法
ES2771226T3 (es) 2016-06-06 2020-07-06 Helsinn Healthcare Sa Formulaciones inyectables de fosnetupitante fisiológicamente equilibrados
ES2884071T3 (es) 2016-07-07 2021-12-10 Sage Therapeutics Inc 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
CN110023323A (zh) 2016-09-30 2019-07-16 萨奇治疗股份有限公司 C7取代的氧固醇及其作为nmda调节剂的方法
CA3041088C (en) 2016-10-18 2024-05-21 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MA46565A (fr) 2016-10-18 2019-08-28 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
CN110730662A (zh) 2017-04-10 2020-01-24 才思治疗公司 用于治疗共核蛋白病的nk1-拮抗剂组合和方法
KR20200026920A (ko) 2017-06-30 2020-03-11 체이스 테라퓨틱스 코포레이션 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법
WO2019038656A1 (en) 2017-08-21 2019-02-28 Leiutis Pharmaceuticals Pvt, Ltd NEW TRIPLE COMBINATION FORMULATIONS FOR ANTIEMETIC THERAPY
CN109694390A (zh) * 2017-10-24 2019-04-30 齐鲁制药有限公司 一种福沙匹坦氮氧化物
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
AU2019223237A1 (en) * 2018-02-26 2020-09-03 Ospedale San Raffaele S.R.L. NK-1 antagonists for use in the treatment of ocular pain
EP3833668A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP4117673A1 (en) 2020-03-11 2023-01-18 Ospedale San Raffaele S.r.l. Treatment of stem cell deficiency
KR20220165251A (ko) 2020-04-03 2022-12-14 네르 쎄라퓨틱스 리미티드 패혈증, 패혈성 쇼크, 급성 호흡 곤란 증후군 (ards) 또는 다발성 기관 기능장애 증후군 (mods)으로부터 선택된 질환을 치료하기 위한 nk-1 수용체 길항제
US11872222B2 (en) 2020-06-02 2024-01-16 Nerre Therapeutics Limited Uses
US20240024339A1 (en) 2020-11-19 2024-01-25 Nippon Kayaku Kabushiki Kaisha Composition containing water-soluble drug causing vascular disorder, solution for use in preparation of administration solution containing water-soluble drug causing vascular disorder, kit, agent for suppressing vascular disorder, and solution containing nonionic surfactant
US11541066B2 (en) 2021-03-04 2023-01-03 Extrovis Ag Stable ready-to-use parenteral compositions of fosaprepitant
CN113582982B (zh) * 2021-06-15 2023-06-16 山东罗欣药业集团股份有限公司 一种nk1受体拮抗剂的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA676161A (en) * 1963-12-17 Hoffmann Karl Benzimidazolyl-acetic acid derivatives and process for their manufacture
US2943022A (en) * 1958-02-25 1960-06-28 Ravensberg G M B H Substituted 1-phenyl-2, 3-dimethyl-4-morpholino methyl pyrazolone-(5) compounds and process of making same
DE1138057B (de) * 1958-04-03 1962-10-18 Ravensberg G M B H Chem Fab Verfahren zur Herstellung von 1-Phenyl-2, 3-dimethyl-4-morpholino-methyl-pyrazolon-(5)-derivaten
GB852727A (en) * 1959-06-24 1960-11-02 Ravensberg G M B H Analgesic compounds
US3458509A (en) * 1966-10-24 1969-07-29 Dow Chemical Co 4-allyltetrahydro-dimethyl-2h-1,4-thiazines
DE1670840A1 (de) * 1967-03-31 1971-03-11 Bayer Ag Verfahren zur Herstellung von Tetra-hydro-1,4-thiazin-1,1-dioxiden
US3506673A (en) * 1968-03-29 1970-04-14 Aldrich Chem Co Inc 2-(4'halo)-benzhydryl-3-quinuclidinols
GB1452701A (en) * 1974-05-07 1976-10-13 Ici Ltd Morpholine derivatives
IE50355B1 (en) * 1979-10-20 1986-04-02 Wyeth John & Brother Ltd Morpholine derivatives
US4476311A (en) * 1980-03-12 1984-10-09 The Purdue Frederick Company Analgesic 4-carboxy-pyrrolidin-2-one compound
DE3134842A1 (de) * 1981-09-03 1983-03-17 Boehringer Ingelheim KG, 6507 Ingelheim Neue anilino-1,2,3-triazol-derivate, diese enthaltende arzneimittel sowie verfahren zu deren herstellung und deren verwendung
FR2534915B1 (fr) * 1982-10-26 1985-10-25 Lafon Labor Nouveaux derives de 2-(phenoxymethyl)-morpholine, utilisation en therapeutique et procede de preparation
US4435395A (en) * 1983-03-03 1984-03-06 Usv Pharmaceutical Corporation N-Substituted 1,4-dihydropyridazines and pharmaceutical compositions
DE3421810A1 (de) * 1984-06-12 1985-12-12 Basf Ag, 6700 Ludwigshafen Phenylalkylamine - bioregulatoren
FR2612926B1 (fr) * 1987-03-24 1989-06-09 Adir Nouveaux derives de la morpholine, leur procede de preparation et les compositions pharmaceutiques les renfermant
DE3800977A1 (de) * 1988-01-15 1989-07-27 Ant Nachrichtentech Digitalsignal-uebertragungssystem mit linienersatzbetrieb
US5064838A (en) * 1988-01-21 1991-11-12 Merrell Dow Pharmaceuticals 1,4-disubstituted-piperidinyl compounds as pain relievers
EP0343900A3 (en) * 1988-05-23 1991-07-03 Glaxo Group Limited Piperazine compounds
EP0360390A1 (en) * 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
DE3901244A1 (de) * 1989-01-18 1990-07-19 Basf Ag Phenylalkylamine und diese enthaltende fungizide
US5070090A (en) * 1989-05-15 1991-12-03 Janssen Pharmaceutica N.V. Antipicorpaviral herterocyclic-substituted morpholinyl alkylphenol ethers
WO1991009844A1 (en) * 1990-01-04 1991-07-11 Pfizer Inc. Substance p antagonists
DK0532527T3 (da) * 1990-06-01 1995-01-02 Pfizer 3-amino-2-arylquinuclidiner, fremgangsmåde til fremstilling deraf og farmaceutiske præparater indeholdende disse
DK178590D0 (da) * 1990-07-26 1990-07-26 Novo Nordisk As 1,4-disubstituerede piperaziner
JPH0772175B2 (ja) * 1990-09-28 1995-08-02 フアイザー・インコーポレイテツド 窒素含有非芳香族複素環の縮合環類似体
US5138060A (en) * 1991-01-03 1992-08-11 Pfizer Inc. Process and intermediates for preparing azabicyclo(2.2.2)octan-3-imines
WO1992012151A1 (en) * 1991-01-10 1992-07-23 Pfizer Inc. N-alkyl quinuclidinium salts as substance p antagonists
US5254569A (en) * 1991-01-14 1993-10-19 The Du Pont Merck Pharmaceutical Company (Amidomethyl)nitrogen heterocyclic analgesics
ATE154354T1 (de) * 1991-02-11 1997-06-15 Merck Sharp & Dohme Azabicyclische verbindungen, diese enthaltende pharmazeutische zubereitungen und ihre therapeutische verwendung
US5459270A (en) * 1991-08-20 1995-10-17 Merck Sharp & Dohme Limited Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them
DK0533280T4 (da) * 1991-09-20 2005-02-28 Glaxo Group Ltd Ny medicinsk anvendelse af tachykininantagonister
CA2099233A1 (en) * 1992-06-29 1993-12-30 Conrad P. Dorn Morpholine and thiomorpholine tachykinin receptor antagonists
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
FR08C0019I2 (fr) 2009-10-30
JP3073770B2 (ja) 2000-08-07
BG62811B1 (bg) 2000-08-31
HU9602409D0 (en) 1996-11-28
CA2183250A1 (en) 1995-09-08
LV11688B (en) 1997-06-20
TW385308B (en) 2000-03-21
WO1995023798A1 (en) 1995-09-08
DE122008000037I1 (de) 2008-11-06
EP0748320A1 (en) 1996-12-18
PL316143A1 (en) 1996-12-23
YU14495A (sh) 1999-07-28
JPH09509935A (ja) 1997-10-07
NO963675D0 (no) 1996-09-03
ATE227722T1 (de) 2002-11-15
CN1147254A (zh) 1997-04-09
FI963450A (fi) 1996-09-03
AU1975095A (en) 1995-09-18
FI963450A0 (fi) 1996-09-03
HUT76324A (en) 1997-08-28
FR08C0019I1 (ko) 2008-07-18
ES2184794T3 (es) 2003-04-16
CZ288241B6 (en) 2001-05-16
CO4340689A1 (es) 1996-07-30
LV11688A (lv) 1997-02-20
AU700611B2 (en) 1999-01-07
NZ282586A (en) 1998-07-28
US5691336A (en) 1997-11-25
MX9603845A (es) 1997-07-31
NO310074B1 (no) 2001-05-14
CN1075812C (zh) 2001-12-05
IL112778A0 (en) 1995-05-26
DE69528823T2 (de) 2003-07-03
HRP950099A2 (en) 1998-04-30
CA2183250C (en) 2006-03-21
ZA951780B (en) 1995-11-15
NO963675L (no) 1996-11-04
BR9507046A (pt) 1997-09-09
US5716942A (en) 1998-02-10
EP0748320B1 (en) 2002-11-13
US5780467A (en) 1998-07-14
US5512570A (en) 1996-04-30
PL180522B1 (pl) 2001-02-28
SK112396A3 (en) 1997-03-05
DE69528823D1 (en) 2002-12-19
CZ258896A3 (en) 1997-03-12
BG100798A (bg) 1997-03-31
RU2170233C2 (ru) 2001-07-10

Similar Documents

Publication Publication Date Title
KR977001713A (ko) 모르폴린 태키키닌 수용체 길항제의 프로드러그(Prodrugs of morpholine tachykinin receptor antagonists)
JP3071467B2 (ja) 置換モルホリン誘導体およびその治療剤としての使用
EP1400518B1 (en) Heterocyclic compound derivatives and medicines
JP2023181543A (ja) ヒト血漿カリクレイン阻害剤
KR950702193A (ko) 모르폴린 및 티오모르폴린 태키키닌 수용체 길항제(Morpholine and thiomorpholine tachykinin recceptor antagonists)
BG100715A (bg) Морфолини и тиоморфолини като антагонисти на тахикининови рецептори
RU96120078A (ru) Пролекарства морфолиновых антагонистов рецепторов тахикинина
US10167280B2 (en) Substituted oxopyridine derivatives
JP3126736B2 (ja) 抗精神病療法
EP2198864A1 (en) Pharmaceutical compositions having an analgesic effect and containing 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino propionic acid amides or related compounds
CN101381345A (zh) 四氢喹啉衍生物及其制备方法
JPWO2002088084A6 (ja) 複素環誘導体及び医薬
TW201604190A (zh) 吲哚啉－２－酮或吡咯并－吡啶－２－酮之衍生物
MA27726A1 (fr) Derives de 4-(4-(heterocyclylalkoxy)phenyl-1-(heterocyclyl-carbonyl) piperidine et composes associes servant d'antagonistes d'histamine h3 destines au traitement de troubles neurologiques
CA2961981A1 (en) Substituted oxopyridine derivatives
US20180250280A1 (en) Substituted oxopyridine derivatives
JPWO2003022821A1 (ja) ２０−ｈｅｔｅ産生酵素阻害作用を有するヘテロ環誘導体
KR101764458B1 (ko) 치환 피리딘 화합물
DE68917170T2 (de) Pyridin-Derivate.
WO2008109287A1 (en) Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
US9314466B2 (en) Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
AU2020360970A1 (en) Prostaglandin E2 (PGE2) EP4 receptor antagonists
CZ349999A3 (cs) Nové pyridinové deriváty a farmaceutické prostředky s jejich obsahem